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Abstract 
Globally, breast cancer is the leading cause of death in the female population aged 45 and 
below with a breast cancer incidence reaching 18.1 million in the year 2018. Triple negative 
breast cancer (TNBC) is part of a group of cancers that lack the expression of Progesterone 
receptor (PR), Estrogen receptor (ER) and Human epidermal growth factor receptor 2 (HER2). 
TNBC is commonly associated with early stage metastasis with low survival rates as well as a 
high frequency of recurrence and proves to be problematic in both the young and elderly female 
populations. Conventional diagnostic methods for TNBCs include mammography, magnetic 
resonance imaging (MRI) and ultrasound while therapeutic methods include mastectomy and 
breast conserving surgery (coupled with radiation therapy). The lack of effective therapeutic 
options, poor prognostic value and high rates of metastasis, has made treatment of TNBC 
difficult. 
The major focus of this work was on the following tumour associated antigens (TAAs): CSPG4 
(a transmembrane protein found in 50% of TNBC cases), EGFR (which is overexpressed in 
13-76% of TNBCs), and MSLN (which is overexpressed in 67% of TNBCs) as potential targets 
for monospecific therapy. The evolution of antibody-based immunotherapy strategies has led 
to applications of single chain variable fragment (scFv) & single domain/nanobody (VHH) 
antibody formats for diagnostic and therapeutic purposes. In this work, these recombinant 
antibody fragments have been combined with SNAP-tag, a modified version of the human 
DNA repair enzyme O6-alkylguanine-DNA-alkyltransferase (AGT), which autocatalytically 
binds benzyl-guanine modified substrates such as fluorophores or small molecule toxins 
covalently in a 1:1 stoichiometry.  
In this study, the primary aim was the comparison of different antibody formats fused to SNAP-
tag and the potential of these biopharmaceuticals towards immunodiagnosis and therapy of 
TNBCs. First functionalities of two scFv SNAP fusion proteins and one VHH SNAP fusion 
protein previously not having been described are provided through binding analyses on 
receptor positive tumour cell lines. 
This was achieved by in-silico design and molecular cloning of genetically fused anti-
CSPG4(scFv), -MSLN(scFv), -MSLN(VHH), -EGFR(scFv) & -EGFR(VHH) to SNAP-tag. 
The final constructs were confirmed by Sanger sequencing and subsequently transfected into a 
mammalian vector system (HEK293T) for transient expression of the engineered fusion 
proteins. Full length protein purified from cell culture supernatant was analysed for 
diagnostic/therapeutic activities dependant on the substrate attached in the form of a 
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fluorophore or small molecule toxin resulting in recombinant antibody-drug conjugates 
(ADCs). The study shows promise in providing new immunodiagnostic and therapeutic agents 
that are specific and less harmful than the current state of the art procedures. 
Key words: TNBC, CSPG4, MSLN, EGFR, scFv, VHH, SNAP-tag 
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Chapter 1: Introduction  
1.1 Breast cancer and triple-negative breast cancer 
Breast cancer is the leading cause of cancer-related deaths in women below the age of 45 
worldwide, due to its heterogeneity and complexity [1]. Some biological risk factors of breast 
cancers include early menarche, late menopause, late aged pregnancies and short or no periods 
of breast feeding and some lifestyle risk factors include obesity, alcoholism and hormone 
replacement therapy or inactivity [2]. In 2004, South African women showed an increasing 
incidence of 5-10 per 100 000, with women living an urban lifestyle having a greater risk of 
getting disease [3]. In developing countries, about 55% of the population are dealing with the 
burden of breast cancer related deaths with an increasing incidence of breast cancer in 
developed countries [4]. As per the World Health Organization (WHO), 2018, the current 
global breast cancer burden is recorded at 18.1 million cases worldwide and the cancer 
mortality is 9.6 million. Breast cancer has also been identified as an increasing problem in 
developing countries e.g. African countries [5].  
Invasive breast cancers are classified into 5 subtypes according to their expression of certain 
genes, including expression of estrogen receptor (ER), progesterone receptor (PR) and human 
epidermal growth factor receptor 2 (HER2). These subtypes are classified as normal breast-
like, HER2 overexpressing, luminal A (ER and PR-positive, HER2-negative), luminal B (ER 
and PR-positive, HER2-positive or negative) and basal-like or triple negative breast cancers 
(TNBC, lack of ER, PR and HER2 expression) [6], [7]; as illustrated in Figure 1. For the 
purposes of this study, the focus will be on basal-like breast cancers. Basal-like breast cancer 
are a unique group of cancers due to their lack of immunohistochemical expression of HER2, 
ER and PR. Approximately 80% of TNBC are basal-like cancers which are clinically and 
immunohistochemically distinct [8], [9]. 
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Figure 1. Classification of tumour subtypes, their prognosis and aggression profiles. Triple negative breast cancers (orange) 
consists of three subtypes including basal-like, claudin-low and mucinous breast carcinoma (MBC). This subset of tumours 
show the worst prognosis and are highly aggressive tumours in comparison to the other subtypes i.e. Luminal A, B and HER2+. 
Adapted from Dai et al. 2017 [10]. 
 
Thus, it would be impractical to use hormone-based therapies and it would not be cost-effective 
to have routine genetic profiling in hospitals [11]. However, gene expression techniques can 
identify basal-like cancers, which have been suggested to be almost entirely made up of TNBCs 
[12]. This subtype of breast cancer accounts for only 12-17% of all breast cancer related cases, 
but is the leader in terms of early stage metastasis as well as cancer recurrence [13]. The 
prevalence of TNBC has been largely in young women of African descent, but has also been 
seen in American and Hispanic women and TNBC accounts for 12-15% of all breast cancers 
[14]. Furthermore, TNBCs are associated with poor prognosis and premenopausal women [15]. 
Scientists have yet to confirm whether the disease is molecularly different in African 
populations or if there is a genetic predisposition to the disease [16]. 
 
1.2 A brief overview of current treatments and their limitations. 
1.2.1  Conventional and modern approaches for TNBC diagnosis & 
treatment. 
Early diagnosis is pivotal in ensuring timely treatment of cancers. Conventional tools for breast 
cancer identification include imaging techniques such as mammography, magnetic resonance 
Tumor 
subtypes







Better prognosis Poor prognosis 
Less aggressive More aggressive 
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imaging (MRI) and ultrasound. Boisserie-Lacroix et al. 2014,  visualized round to oval lobular 
cells with undefined, micro-lobulated or rimmed margins using the above mentioned imaging 
techniques [17]. The limitations of this technology are that it is not readily available to low-
income countries, also requiring skilled professionals to operate them [18] and moreover these 
techniques have been shown to give false-positives [19], leading to unnecessary and costly 
treatments. This is because TNBC usually shows benign or intermediate tumours on ultrasound 
and mammography as shown by Zhang et al., 2017. Surgery, such as mastectomy, and radiation 
are preferred methods of treatment but are accompanied by risks such as higher toxicity levels 
with increased dosages and long treatment schedules, resulting in the death of healthy tissues 
and complications during surgery [20]. The rise of new technologies such as molecular 
subtyping or precision medicine have revolutionized cancer classification [21]. Molecular 
subtyping has shown that surgery, in particular breast-conserving surgery (BCS), is more 
favourable in luminal A cancers as opposed to TNBCs [22]. However, a study has shown 
locoregional outcomes that mimic those of mastectomies through surgery and post-surgery 
radiation that gave a low risk of recurrence for over a 5-year study period in women with T1-
2N0 TNBC [23]. Age is also thought to be a contributing factor to locoregional recurrence 
(LRR) and survival of breast cancer patients. A lower age has been associated with more 
positive results amongst the different subtypes, but a study by Kuijer & King, 2017, showed 
that surgical therapy results from both BCS or mastectomy and does not differ significantly 
amongst age groups, but that tumour biology is the main predictor of pathology [24].  
The conventional administration of radiotherapy for TNBC is the same as in other breast 
cancers post BCS or mastectomy, but is still a controversial issue [9] as the effectiveness of 
early stage radiation after mastectomy or BCS in T1-2N0 may not be the same as in other 
cancer subtypes [25]. The effectiveness of adjuvant radiotherapy is still under scrutiny by the 
scientific community, but a study by Bhoo-Pathy et al., 2015, compared adjuvant radiotherapy 
with BCS and mastectomies for TNBC in a cohort of Asian women. Radiotherapy was 
associated with higher survival rates in younger women, but overall BCS and mastectomies 
were associated with a decreased risk of disease [26]. Designating specific treatments for 
heterogenous breast cancer subtypes would improve the management of early breast cancer as 
stated in the 14th St Gallen International Breast Cancer Conference of 2015 [27], but recent 
work has suggested that breast cancer subtypes and their genetic assays can be useful in the 
thought process for radiation therapy, by serving as predictive biomarkers and prognostic 
information that is critical in future clinical research [28]. 
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Although TNBC prognosis remains poor, this subset of cancers responds better to 
chemotherapies as compared to the other cancer subsets [29]. Common chemotherapy 
regimens to manage TNBC include damaging cell integrity using platinum compounds, taxanes 
and anthracycline containing regimens leading to loss of cell proliferation and apoptosis 
induction [30]. Some chemotherapy regimens are not defined for early and advanced stages of 
TNBC and makes using the appropriate dosages for chemotherapy very challenging [31]. 
However, third-generation chemotherapy regimens that utilize dose dense polychemotherapy 
as an effective regimen that is available and administration of chemotherapy preoperatively has 
become a standard in clinical practice [32]. Systemic treatments include cytotoxic, 
immunotherapeutic and hormonal agents, which can be used as adjuvant, neoadjuvant and 
metastatic treatment. Systemic adjuvant therapy is used post-surgery when an individual is 
expected to relapse and neoadjuvant is used for patients with locally advanced and inflamed 
breast cancer [33]. Cytotoxic treatments use a target based system e.g. targeting HER2 and 
using drugs such as trastuzumab and lapatinib, which then deliver antibody targeted cytotoxic 
effects to the tumours but these are still ineffective against TNBCs [34]. Due to the lack of a 
suitable conventional therapy against TNBCs, the discovery of novel biomarkers and 
therapeutic strategies is of high importance. 
 
1.2.2  Cancer Immunodiagnosis & Immunotherapy 
Immunodiagnosis is a broad field that focuses on the discovery, evaluation, validation and 
application of markers that provide critical information about a patient’s disease states, both 
pre-and post-therapy, while also predicting the responses to immunodiagnostic agents and 
immunomodulatory or cytotoxic drugs. Immunodiagnostic markers may be either cell-specific, 
which may be classified as: i) histopathological (based on cell morphology assessments) or ii) 
immunophenotypic (based on immunohistochemical (IHC) assessments). The markers can be 
tumour-specific; classified as 1) Immune-response related gene expression profiles and 2) 
Tumour genotype characteristics, assessed by large scale genotypic methods such as next 
generation sequencing (NGS) [35].  
Immunotherapy is an arm of targeted therapies that seeks to utilize an individual’s adaptive 
and innate immune responses to combat disease. It encompasses a passive approach (in the 
introduction of ex-vivo agents such as antibodies and other immune cells) which does not 
stimulate a host immune response and an active approach stimulates an immune response and 
promotes the development of immune effector cells such as antibodies or T-cells [36]–[38]. 
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Immunotherapy offers an alternative to chemotherapy and hormone therapy, such as the 
blocking of CTLA-4, which functions in the down-regulation of T-cell responses activated by 
tumour development, but this method of treatment is limited to intrinsic immunogenic tumours 
[39]. Hormonal therapy with tamoxifen or aromatase inhibitors have shown clinical efficacy, 
but issues are found when the patient takes the incorrect dosages or discontinues treatment, 
which suggests that the treatment is only effective when taken for extended periods of time 
[40]. Cancer immunotherapy has shifted the paradigm of cancer therapies which is necessary 
for cancers that cannot be treated by conventional means, such as TNBC [41], [42]. There are 
various types of immunotherapy which include T-cell based therapies, T-cell engineering & 
Antibody based therapies. An example of T-cell based therapies is the use of vaccines which 
is a host-directed immunotherapy [43]. Since their introduction by Edward Jenner and his 
smallpox vaccine in 1796 [44], there have been various types of vaccines that have been 
designed such as: Live attenuated vaccines (makes use of a weakened strain of a pathogenic 
inducing long-lived immunity to disease but is not suitable for the immunocompromised due 
to adverse immune effects [45]); Inactivated vaccine (comprised of a killed pathogen that 
cannot double in number but the immune response is relatively weak [46]); Subunit vaccine (A 
highly secure vaccine that focuses on inducing an immune response for the most dominant 
epitopes on a pathogen but normally requires more than one dose [47]); Toxoid vaccine 
(induces a strong and lasting immune response to the toxin of the pathogen but an additional 
dose may be required [48]); Conjugate vaccine (a vaccine that is safe for infants that consists 
of a protein fused to a weak antigen from a pathogen which induces a lasting immune response 
but it is relatively expensive to make [49]); DNA vaccine (a non-infectious vaccine that uses 
fragments of DNA that encode for certain antigens from pathogens but is limited to the 
production of protein antigens [50]) and Recombinant vaccines (introduces recombinant DNA 
using a viral or bacterial vector producing a strong immune response but vector immunity may 
result in adverse immune effects [51]).  
T-cell engineering is an arm of medicine that makes use of genetic engineering and molecular 
biology techniques to produce synthetic probes to combat a variety of diseases by recruiting 
and activating T-cells [52], [53]. Examples of these synthetic probes include Bispecific 
antibodies (BsAbs) which have two binding sites that work synergistically and are able to bind 
different epitopes with different specificities [54]. Other BsAbs formats have been used such 
as bi-specific T-cell engagers (BiTEs), dual affinity re-targeting antibodies (DARTs) and 
Tandem diabodies but the antibody formats that are commonly used in present day are single 
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chained variable fragments (scFv) and single domain antibody (SdAb) formats [55]. Antibody 
or ligand based therapies have the goal of eliminating or neutralising diseased cells by 
inhibiting the functionality of certain substances, specific targeting of diseased cells or by 
adopting the role of signalling molecules [56]. 
Antibody conjugates are different formats of antibodies fused an effector molecule(s), 
examples of these include radionuclides to form radioimmunotherapy which uses mAbs 
combined with radioisotopes to treat diseases such as low-grade lymphoma  [57], [58] but the 
downfall to this technology is that the radiation is not limited to the target organ but continues 
in circulation, decays and harm healthy tissues [59]. Immunotoxins are a combination of a 
targeting domain and a toxic protein and, in most cases a bacterial or plant derived toxin, in 
order to treat disease [60]. Historically, immunotoxins would induce a neutralizing immune 
response but immunogenicity can be greatly reduced by removing the B or T-cell epitopes from 
the protein toxins and humanization of bacteria/plant toxins [61], and prime candidates for 
immunotoxin research include granzyme B, angiogenin, DAP-K and Map-Tau [62]–[66]. 
Specific novel immunotherapeutic agents such as antibody drug conjugates (ADCs) including 
human cytolytic fusion proteins (hCFPs) and immunotoxins (IT) hold promise in being 
treatments for breast cancers and other diseases [67]. ADCs have the ability to transfer toxic 
agents to specific tumour cells. hCFPs are a class of humanized immunotoxins that contains a 
ligand which binds specifically to target cells, which have an apoptosis inducing enzyme 
genetically attached. hCFPs can bind to targeted cancer cells by any type of recombinant 
antibody or scFvs [68]. There are currently only two ADCs that are FDA approved, Ado-
trastuzumab (which is a HER-2 targeting conjugate that exerts its cytotoxic effects by inhibiting 
microtubule assembly) and Brentuximab Vedotin (which targets CD30 on Hodgkin and 
anaplastic large cell lymphomas but has also been used for HIV treatment [69]–[71].  
 
1.2.3  ScFv and Nanobody formats as a branch of Immuno-diagnostics & 
therapy 
Monoclonal antibodies (mAbs) have been established as biotherapeutic proteins that are used 
as modes of treatment for a variety of diseases [72]. The use of animal serum containing 
polyclonal antibodies and toxins saw the dawning of antibody based therapies which sired 
hybridoma technology (1975) and the eventual rise in the use of mAbs which impacted the 
pharmaceutical industry [73]. mAbs are an example of immunotherapeutic agents that can 
induce cellular toxicity by antibody or complement dependent cytotoxicity [74]. As of 2017, 
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there are 61 mAbs in clinical use but only two mAb’s, trastuzumab and cetuximab, are 
approved for therapy in breast cancer [75]. The utilization of mAbs for cancer therapy may 
have proven to be efficacious by activating inhibitory immune complexes, altering tumour-
relating signalling pathways and inducing immune responses against tumours but only have 
intermediate activity in reducing tumours and therefore have to be administered in high doses 
[76]. 
 
Table 1. The advantages and disadvantages of monoclonal and single domain antibody formats. Adapted from Runcie et 
al, 2018 [77] and ProSci, 2018  (https://www.prosci-inc.com/resources/antibody-development-guide/antibody-structure-
and-properties/). 
 Antibody format 
Monoclonal antibody Single domain antibodies 
Advantages • Highly specific 
• Constant and renewable 
supply 
• Can be used for imaging 
• Homogenic nature allows for 
reproducibility 
 
• Highly specific 
• Constant and renewable 
supply 
• High stability 
• Large scale production at low 
cost. 
• Can be used for imaging. 
• Homogenic nature allows for 
reproducibility. 
• Small size allows for faster 
clearance and therefore low 
immunogenicity. 
• High thermostability and good 
solubility. 
Disadvantages • Limited penetrative ability 
• Long and costly development 
periods 
• Large molecules take longer 
to clear and increases 
potential of aggregation and 
immunogenicity 
• Costly development periods. 
• Targeting single epitope may 
lead to acquired resistance. 
• Extent of genetic engineering 
is limited. 
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• Targeting single epitope may 
lead to acquired resistance 
mAbs are generally Y-shaped molecule with two upper branches (V shape) each housing 
receptor binding regions which contribute towards specificity and affinity. The single stem of 
the molecule is called the Fc or constant region and is responsible for cell killing mechanisms 
and extended half-life in circulation through interactions with Fc receptors [78], [79]. 
Typically, mAbs consists of two light (LC) and two heavy variable chains (HC) that make up 
the fragment antigen binding region (Fab). These chains are held by highly conserved amino 
acid residues (CH1 for the heavy chain and CL for the light chain) extending from the framework 
region of the antibody as seen in Figure 2 [80]. The light chains are categorized under lambda 
(λ) and kappa (κ) class, and the heavy chains are categorized into alpha (α), gamma (γ), delta 
(δ), epsilon (ε) and mu (µ) dependent on the class of immunoglobulins (Ig) [81]. The binding 
component of antibodies have been at the heart of antibody engineering research because of 
their targeting ability. They consist of six complementarity-determining regions (CDRs) i.e. 
three from the HC and LC respectively [82]. The Within the binding domain there is variability 
in the amino acid sequences on the heavy and light chains (VH and VL)  of about 110 amino 
acids, which are the determinants of the antibody isotype, referred to as the V-domain (Fv) 
which confers the specificity of the paratope of the antibody [83], [84]. Antibody derivatives 
can be used as diagnostic or therapeutic tools and are more easily produced than monoclonal 
antibodies. They are usually engineered in the form of fusion proteins [85]. The use of 
engineered antibodies has proven advantageous in fields of research, diagnosis and therapy. 
Although full-length mAbs have provided advancements, their size limits their penetrative 
ability in vivo [86].  
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Figure 2. Schematic diagram of different antibody formats. The illustration shows the development of antibodies in the 
immunotherapy field. Antibody development initially started with full sized monoclonal antibodies to single chain Fv 
fragments and thereafter further improving to single body formats.. Acquired from 
(https://www.hybribody.com/contenu/synthetic-vhh-library-menu/take-advantage-of-vhh-antibody-properties). 
The improvements in antibody engineering have allowed for the synthesis of smaller antibody 
formats without interfering with the paratope of the antibody. The smaller antibody formats 
such as scFv and antigen binding fragments have shown favourable characteristics towards 
diagnostic and therapeutic applications without the limitations seen in the larger antibodies as 
seen in Table 1 [87]. The structure of the scFv molecule consists of variable regions of the 
heavy chain (VH) and light chain (VL) chains bound together by e.g. a serine/threonine linker 
(~3.5 nm in length) [88]–[91]. Furthermore, the scFv antibody shows target specificity and 
affinity in vivo that propelled its development as delivery molecules towards cancer treatment 
[92], [93] It confers some favourable characteristics such as reduced immunogenicity, faster 
clearance from blood circulation and low retention in non-target tissue, and improved tumour 
penetration as compared to full sized antibodies [94]–[96]. This antibody format has been 
genetically modified to be used in conjunction with toxins, drugs and radioisotopes [96]–[98], 
they may be used as gene delivery tools and as anticancer agents [93]. Along with scFv, 
nanobody formats have shown promise in research, diagnosis and therapy. 
Fully functional antibodies consisting of only heavy chain fragments were first found in the 
sera of camelids and described by Professor Hamers research group at the University of 
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Brussels in the early 90s. Nanobodies are single domain antibodies derived from camelid 
immunoglobulins that naturally consist of two variable heavy chains (VHH) and one antigen-
binding domain and are approximately 13-15kDa in size as shown in Figure 2. These 
homodimeric antibodies contain providing advantageous properties such as size, high affinity, 
stability, specificity, low production costs and their generation is less laborious as compared to 
mAbs and scFvs [99]–[102]. The VHH show about 90% similarity to the heavy chain fragment 
of human antibodies thus minimizing their immunogenic response. Furthermore, humanization 
of this antibody by CDR grafting has shown to increased similarity up to 99% [103], [104]. 
CDR grafting is a process that is based on selecting the CDR sequences of the non-human 
antibody and combining this with the framework of a human antibody [105], [106]. As 
previously mentioned, nanobodies naturally show 90% similarity to the VH of human 
antibodies and the humanization of these antibodies could possibly hinder functionality based 
on possibly incorrect amino acid substitutions. A study by Vincke et al, 2009, proposed a single 
humanized nanobody, h-NbBcII10FGLA that was synthesized from nanobody NbBcII10 
(belonging to subfamily-2 of nanobodies), that ensures full retention of antibody stability & 
functionality [107], [108]. The small size of the antibody makes it easier to express high yields 
of antibodies in expression systems and because it is made up of 1 domain, the posttranslational 
modifications are far less complex [101], [103]. The domain stability affinity of nanobodies 
(VHH) is contributed by an additional disulphide bond between CDR 1 and CDR3 regions. 
This link forms an interloping bond which allows for the recognition of different and unique 
epitopes that may be inaccessible to conventional antibodies [102], [109], [110]. Nanobodies 
have the potential to make significant contributions towards advanced microscopy and 
immuno-imaging. Immuno-imaging is an imaging tool with the aim of studying patient 
diseases using radiolabelled Ig probes in conjunction with positron emission tomography. 
Nanobodies are fast and highly specific delivery molecules in vivo and show potential in being 
the new state of the art in diagnostics [100], [111]. 
 
1.3  CSPG4, Mesothelin and Epidermal Growth Factor Receptor targeting SNAP 
fusion proteins as an approach to TNBC antibody-based diagnosis & therapy 
1.3.1  SNAP-tag technology as a powerful tool for diagnosis 
SNAP-tag is a 20kDa modified version of the human DNA repair enzyme O6-alkylguanine-
DNA-alkyltransferase (AGT) which permits site-specific self-labelling of SNAP tag-based 
fusion proteins. This technology can also be used to generate a novel antibody format by its 
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fusion to a recombinant antibody fragment allowing directed conjugation to benzylguanine 
(BG)-modified substrates in a 1:1 stoichiometry [112]. SNAP-tag is unique compared to other 
self-labelling proteins in that it ensures rapid, specific and covalent binding to derivatives, is 
easily producible [113] and are of greater preference compared to conventional small peptide 
tags [114].  
SNAP-tag is a versatile and novel technology that allows for the labelling of covalently linked 
proteins with a variety of fluorophores that contain a BG moiety [115]. SNAP-tag is also 
considered to be an efficient labelling tool due to its multi-purposed mode-of-action. SNAP-
tag can be used to label surface molecules or intracellular organelles, such as cytosolic proteins, 
the nucleus and mitochondria, based on the permeability of the BG substrate [116].  SNAP-tag 
has numerous applications in protein labelling, because its auto-catalytic reaction to BG 
derivatives is independent to the nature of the attached synthetic probe, which allows for the 
labelling of SNAP fusion proteins to a variety of synthetic probes [117]. 
 
Figure 3. Schematic diagram of SNAP-fusion protein reacting with BG-substrates. The scFv or VHH component of the fusion 
protein is recombinantly fused with SNAP-tag which allows for covalent binding with BG-modified substrates in a 1:1 
stoichiometric ratio. 
 
SNAP-tag technology allows for numerous approaches to diagnosing disease such as using a 
targeting SNAP-tag fusion protein conjugated to a BG-fluorophore to identify markers on 
diseased tissues [118]. SNAP-tag can also be used for the treatment of cancer through site-
directed delivery of effector molecules, such as synthetic small molecule toxins, 
photosensitizers or nanoparticles in the form of antibody drug conjugates (ADCs) to diseased 
tissues. SNAP-tag-based ADCs have a multitude of benefits over traditional ADCs. The 1:1 
stoichiometry allows production of homogeneous conjugates, providing a defined drug to 
antibody ratio and facilitating the quantification of pharmacokinetic properties of the 
therapeutic moiety. Additionally, the self-labelling process eliminates the need for additional 
chemical conjugation steps, lends ease and simplicity to the development of such therapeutic 
tools and preserves the structure and function of the antibody, which is not subjected to the 
harsh conditions by chemical modifications. The intermediate size of the scFv-SNAP construct 
Figure 1.
A protein of interest (POI) is fused to the SNAP-tag for expression in cells or in vitro. The
reaction of the SNAP-tag with O6-benzylguanine (BG) derivatives results in the covalent
attachment f the label to the active site cysteine.
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still allows rapid accumulation and efficacious binding to tumour tissue soon after injection, 
together with rapid renal clearance, producing a high tumour-to-background ratio [119]–[121].  
SNAP-tag fusion proteins have thus far been a great success in preclinical xenograft tumour 
models. Live cell imaging approaches to visualize tumour behaviour are more challenging to 
address, specifically since they require use of chemical probes that give off background 
fluorescence due to off-target effects [122], [123]. SNAP-tag technology has also allowed for 
the visualization of live cells by manipulation of SNAP-tag fusion proteins with fluorescent 
labels, but also getting a three-dimensional framework and surface patterns of the cell [124]. 
SNAP-tagged probes have minimal to no off-target effects due to its monovalency and high 
specificity to a single protein of interest when fused to a targeting antibody [125]. 
Improvements have been made to this technology with the design of a variant called SNAP-F. 
SNAP-F was generated by the addition of point mutations a C-terminal deletion that resulted 
in a 19 amino acid difference between SNAP-F and the hAGT sequence , and a 10 amino acid 
difference between SNAP-F the commercially available SNAP-tag [123], [126]. It has been 
shown to be more efficient in terms of versatility, speed, sensitivity and shows up to tenfold 
increased reactivity to BG-substrates in comparison to the conventional SNAP-tag [123], 
[127], [128]. This study will involve synthesizing SNAP fusion proteins that encompass an 
anti-CSPG4, anti-Mesothelin and anti-EGFR scFvs as well as VHH formats conjugated to 
SNAP-tag and the SNAP-F variant. 
  
1.3.2  Chondroitin sulfate proteoglycan 4 (CSPG4) as a target on TNBCs 
CSPG4 was originally described as a transmembrane proteoglycan that functions to facilitate 
the growth and survival of cancer cells. It serves as a highly immunogenic tumour antigen on 
the surfaces of melanoma cells, but has been shown to be expressed in various types of human 
carcinoma and sarcomas [85]. An orthologue of CSPG4, n/glial antigen 2 (NG2), has also been 
described in rats [129], [130]. The functionality of tumour cells associated with CSPG4 can be 
inhibited by the use of CSPG4-specific monoclonal antibodies in vitro and in vivo, and its 
inhibitory properties are thought to stem from the blocking of migratory, proliferative and 
survival pathways of the tumours [131]. CSPG4 has a large extracellular domain, a 25 amino 
acid transmembrane region and a 75 amino acid region intracellularly as shown in the 
illustration below (Fig. 4) [132]–[134]. CSPG4 is constituted by three extracellular domains 
(D1, D2 & D3) which are structurally and functionally distinct leading to the activation of 
factors that trigger cascades in the pathway and transcription [133]. The D1 domain, on the N-
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terminal, is home to a plethora of signalling sites including Laminin G binding sites. Although 
the exact function of laminin domains is unclear, they have been shown to be involved in site-
directed mutagenesis, tumour migration and proliferation through activation of specified 
pathways [135], [136]. The largest extracellular domain (D2) is rich in glycine and serine, and 
is also characterized by chondroitin sulfate glycosaminoglycan (CSGAG) modifications as 
well as N- and O- linked glycosylation sites [137], [138]. The C-terminal D3 is globular region 
involved in N-linked glycosylation and has pronounced carbohydrate modifications that allow 
binding of galectin 3 or other lectins such as p-selectin [12], [139], [140]. The threonine cluster 
consists of Extracellular-signal-regulated-kinase (ERK) 1,2 and Protein Kinase C-alpha 
(PKCα) phosphorylation sites and a PDZ-motif, which comprises of anchoring proteins such 
as syntenin, MUPP1 and GRIP1 [132], [133], [141], [142] to attach the CSPG4 to the actin 
cytoskeleton. Upon phosphorylation of the threonine cluster by ERK 1,2 & PKCα there is 
activation of cell survival and proliferation pathways leading to more cell motility and 
epidermal-mesenchymal transition (EMT) [137], [140].  
 
 
Figure 4. Schematic diagram of the structure of the transmembrane CSPG4 receptor. The organization of CSPG4 consists of 
D1, D2 & D3 extracellular domains, a transmembrane domain a threonine cluster intracellularly. D1 houses Laminin G binding 
sites and D2 is rich with serine and glycine. Adapted from Amoury et al, 2016. 
 
Phosphorylation of the threonine cluster results in the activation of signalling proteins that 
result in cell proliferation which is commonly via the mitogen-activated protein kinase 
(MAPK) and Focal adhesion kinase (FAK) pathway [143], [144]. CSPG4 interacts with the 
anchoring protein, syntenin, promoting the activation of FAK resulting in signalling cascades 
inclusive of FAK-integrin-extracellular matrix (ECM) assembly and activation of 
phosphoinositol 3-Kinase (PI3K)/ protein kinase B (AKT)/ nuclear factor kappa beta 
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(NFKβ)/melanocyte lineage specific transcription factor (MITF) pathways as illustrated in 
Figure 5. The consequence of this activity is cytoskeleton remodelling, cell survival, 
chemoresistance and migration [145], [146]. The activation of CSPG4 also triggers cascades 
associated with receptor tyrosine kinases (RTK) i.e. RAS-RAF-MEK-ERK1,2 [145], [147]. 
The activation of ERK 1,2 by CPG4 results in changes in gene transcription as a result of MITF 
resulting in EMT [148]. 
 
Figure 5. Schematic diagram of CSPG4 pathway leading to cancer survival and metastasis. Adapted from Price et al, 2011. 
 
CSPG4 has evident potential as a target for immunotherapy in breast cancer.  CSPG4 has been 
attributed to P-selectin binding in aggressive cancer cell lines, and contributes to metastasis of 
breast cancer [112]. According to Beard, et al., 2014 and Amoury, et al., 2016, CSPG4 is 
expressed in 50% of TNBC, and therefore is an effective model for monoclonal antibody-based 
treatment, which has been shown to block CSPG4-linked signalling pathways and inhibit 
tumour growth in vitro. In this study, a high affinity anti-CSPG4 (scFv) antibody conjugated 
to SNAP-tag to generate a CSPG4-specific SNAP-tag fusion protein will be used as a novel 
diagnostic tool for TNBC.  
 
1.3.3 Mesothelin as a potential target on TNBCs 
Organs in the abdominopelvic regions of the human body are normally covered by a single 
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fibronectin and collagen I & IV, all originating the mesoderm [149]–[152]. Mesothelin 
(MSLN) is a 40kDa glycosylphosphatidylinositol-linked cell surface antigen that is present in 
normal human tissues. Antigen expression is limited to the linings of pleura, the peritoneum 
and the pericardium of these tissues. The mesothelin antigen is overexpressed in several human 
malignancies, including mesothelioma, pancreatic, ovarian, lung adenocarcinomas and TNBC  
[153]. Mesothelin was initially described in 1992 as a cleavable 70kDa protein resulting in a 
40kDa protein anchored to the membrane by GPI and a 30kDa megakaryote potentiating factor 
(MPF) as seen in figure 6 [154]–[156]. However, with the knowledge of the furin cleavage that 
the precursor undergoes, the three-dimensional structure and biological function of mesothelin 
is still poorly understood. Recent studies have shown that mesothelin is involved in driving 
cancer progression through the interactions with MUC16/CA-125, particularly in 
mesothelioma and ovarian cancer [156]–[160]. The binding motif of MSLN is separated into 
an MCAT  and an SP-1-like region [161], [162]. Previous studies have also shown that the 
eight nucleotides of MCAT are important toward the function of the receptor and mutations in 
the SP-1-like domain are characteristic of cancer progression and metastasis, however, the 
transcription factor that promotes overexpression in human malignancies is yet to be identified 
[163].  
 
Figure 6. Schematic diagram of transmembrane mesothelin receptor. The full mesothelin transmembrane protein is 
cleavable releasing the 30kDA MPF and leaving the 40kDa membrane bound protein (adapted from 
https://www.mdpi.com/2072-6694/10/9/277/htm#B42-cancers-10-00277). 
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Stimulation of mesothelin triggers a cascade that ultimately results in cell proliferation, 
adhesion, survival, migration and invasion by cancerous tissues as seen in Figure 7 [158], 
[164]–[166]. Cancer progression, survival, invasion and resistance as a result of mesothelin has 
been linked to the induction of MMP-7 via the MAPK/ERK & PI3K/AKT pathways resulting 
in the inhibition of proapoptotic family of proteins, such as Bad & Bax, and activation of anti-
apoptotic proteins, such as Bcl-2 & Mcl-1, leading to inhibition of apoptosis (Fig. 7) [167]–
[169]. The MAPK/ERK pathway results in the down regulation of proapoptotic family. The 
phosphorylation of AKT via PI3K activation results in the inhibition of tumour necrosis factor 
(TNF-α) driven apoptosis due to the inhibition of pro-apoptotic family and increased 
expressions of anti-apoptotic proteins [167], [168], [170]. The overexpression of MSLN on the 
cell surface has shown to increase the levels of interleuken-6 (IL-6) which activates 
transcription factor protein 3 or Stat3. Stat3 results in the upregulation of cyclin E/cyclin-
dependent kinase (CDK2) complex, activating the cell cycle and also accelerating the G1-S 
phase transition, contributing to proliferation of cancerous cells [164], [166]. 
 
Figure 7. Schematic diagram of Mesothelin pathway leading to cancer survival and cell proliferation. Adapted from Tang 
et al, 2013. 
 
MSLN is not characteristically expressed in breast cancer but a study by Tchou et al, 2012, 
found that the surface antigen is expressed in about 67% of TNBC tissues [171]. In normal 
tissues, mesothelin is expressed on mesothelial cells which are expendable, thus making it an 
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[160], [172]. Attempts towards a long-lasting therapy for mesothelin related cancers have been 
made. These include antibody-based therapy such as immunotoxins, chimeric monoclonal 
antibody & antibody-drug conjugates, as well as mesothelin vaccines but no long-lasting 
therapies have been described [156], [173]. Different imaging platforms have shown successful 
imaging data on mesothelin related cancers which is are important steps to improving 
immunodiagnostics of these diseases. In a study by Weele et al, 2015, an αMSLN antibody 
was labelled with zirconium, a strong & malleable metal, to assess the biodistribution of MSLN 
in mice with pancreatic tumours using micro PET imaging [174]. A different study, made use 
of immunoPET imaging making use of a phase I αMSLN antibody conjugated to monomethyl 
auristatin E (MMAE) and MSLN expression, tumour uptake & whole body distribution in 
patients with pancreatic and ovarian cancers [175]. Another study by Prantner et al, 2015, 
produced αMSLN nanobodies that could recognize native and denatured mesothelin antigens 
using optical imaging, flow cytometry & immunofluorescence [86]. In this study, a high 
affinity anti-MSLN scFv and VHH recombinantly fused to SNAP-tag to generate a MSLN-
specific SNAP-tag fusion protein will be used as a novel diagnostic tool for TNBC.  
 
1.3.4 Epidermal Growth Factor Receptor (EGFR) as a potential target on 
TNBCs. 
EGFR is a transmembrane protein that is a member of the ErbB family of receptor tyrosine 
kinases. It is activated when bound to peptides of the EGF-family. This group of RTKs protein 
consists of four members which are ErbB2/HER2, ErbB3/HER3 ErbB4/ HER4 and EGFR. 
EGFR is a 170 to 185kDa glycoprotein, also known as HER-1 or c-ErbB-1 and was the first 
member of this RTK to be described. There has been confirmation of EGFR involvement in 
progression of cancers of the lung, oesophagus and breast tissues when the protein is 
overexpressed, making it an attractive target [176]–[181]. The structure of each RTK is made 
up of an extracellular ligand binding domain, a single transmembrane domain (TM) and an 
intracellular domain with tyrosine function. Characteristically, members of ErbB family consist 
of an extracellular domain abundant in cysteine at the N-terminus, a hydrophobic 
transmembrane region and a highly conserved intracellular C-terminus with many 
phosphorylating sites as shown in Figure 8 [182]–[184]. The extracellular domain of EGFR is 
made up of 4 subunits (I, II, III & IV) that have open and closed conformations. The open 
conformation is considered as the active form as it allows binding to the corresponding ligands 
at regions I & II. Subunits II & IV interact with each other in the inactive form or closed 
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conformation thus prohibiting the binding of any ligands [184]–[187]. ErbB receptors are 
regulated by at least 12 different growth factors which include transforming growth factor-α 
(TGF-α) and EGF. Activation of RTK begins when ligand (growth factor) binds to the 
extracellular receptor domain, which triggers the homo and/or heterodimerization of the 
receptor, follow by internalization within the cell [188], [189]. 
 
Figure 8. Schematic diagram of transmembrane EGF receptor. Extracellularly EGFR has four subunits that may be in an open 
(active) or closed (inactive) conformations. This region has  It has a hydrophobic transmembrane region and a highly 
conserved intracellular domain that houses the tyrosine kinase domain and has autophosphorylation sites (adapted from 
https://www.hindawi.com/journals/jo/2010/568938/fig1/). 
 
Mutations in this protein have also shown an increase in the activation of the downstream 
signalling pathways such as RAS-RAF-MEK-ERK-MAPK and AKT-PI3T-mTOR pathways, 
resulting in proliferation of the diseased tissues (Fig. 9) [190], [191]. Upon internalization, 
intracytoplasmic tyrosine kinase domain of the EGFR is autophosphorylated and assists in 
recruiting signal transducers and activators of intracellular substrate such as Rat sarcoma (Ras). 
Once activated, Ras will activate downstream signaling cascades such as 
RAF/MEK1/2/ERK1/2 and/ or PI3k/Akt which will culminate in translocation of their effector 
molecules (e.g.: ERK1/2) into the nucleus where they will control the transcriptional activity 
of genes regulating cell proliferation, survival, differentiation and migration [191].  
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Figure 9. Schematic diagram of EGFR leading to cancer proliferation and migration. Adapted from Krawczyk et al, 2009. 
Overexpression of EGFR has been shown to be a problem particularly in breast cancers. 
Approximately 50% of TNBC overexpress EGFR and there is currently no adequate therapy 
for this disease. EGFR inhibiting agents have been looked at as a possible therapy but showed 
poor results [179]. There are currently two monoclonal antibodies, cetuximab and 
panitumumab, in clinical practice that target for EGFR [192]. EGFR targeting radiolabelled  
nanobodies have been used in a study by Piramoon et al, 2017, showed promising results in 
hindering progression of cancer in nude mice [193]. Recent advancements in therapies, the 
diagnostic aspect also requires some improving. A study by Lee et al, 2017, used PET/CT 
scanning & immunohistochemistry on breast cancer to assess the uptake and it was shown that 
high breast tumour rates are strongly influenced by the presence of EGFR [194]. A novel 
fluorescent probe, (EGF)-Cy5.5, coupled with an anti-EGFR monoclonal antibody was tracked 
in vivo using continuous wave fluorescence imaging and near-infrared (NIR) optical imaging. 
This imaging method showed that it is possible to have images while using low doses of 
fluorophore (1 nmol/mouse), but it still held some limitations such as background fluorescence 
in the mice and the emission period of the NIR dyes used [195], [196], [196]. In this study, a 
high affinity anti-EGFR scFv and VHH recombinantly fused to SNAP-tag to generate a EGFR-
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1.4 Aims & Objectives 
TNBC is an aggressive subset of breast cancers that mainly affects young premenopausal 
women. There is currently has no adequate long-lasting form of therapy for this disease. This 
study aims to generate novel immunodiagnostic agents (scFv and VHH antibodies) that target 
surface antigens known to be overexpressed in TNBCs (CSPG4, MSLN and EGFR), and 
utilizing SNAP-tag® technology toward this goal. Furthermore, the performance of the VHH 
antibody format against the scFv when combined with SNAP-tag® technology will be 
evaluated. Previous work suggests that features of the  VHH shows more favourable results in 
comparison to the scFv [197], [198]  and we seek to investigate if the binding capacity is 
affected by the conjugation of SNAP-tag®. The plasmid system encompasses the genes of the 
targeting molecule (scFv/VHH), Ampicillin and Zeocin/Bleomycin resistance genes for 
selection of transformed clones in bacterial culture and transfected cells in mammalian cultures. 
The plasmid also contains an enhanced green fluorescent protein (EGFP) gene that serves as a 
reporter of protein production in mammalian cultures. The proteins will be evaluated on their 
producibility in culture with the fluorescence of the EGFP reporter protein and efficiency data 
drawn from this. The proteins will also be evaluated on the ability to bind BG-modified 
molecules (testing the SNAP-tag component of the protein) and the ability to bind surface 
antigens on tumour cell lines (testing the specificity of the scFv/VHH) both visualized using 
confocal microscopy. The long-term aim of this work is to ensure a novel combination product 
that can be used for diagnostic purposes of CSPG4, MSLN & EGFR positive cancer cells as 
well as for directed therapies by replacing the diagnostic label by a therapeutic label.  
This research also serves as a foundation for further studies directed at in vitro binding of 
SNAP-tag and its potential applications in various fields of study. This project seeks to 
ultimately develop a diagnostic tool that encompasses ER, PR, HER2, MHC1 (major 
histocompatibility complex 1), EpCAM and PDL-1 (programmed death ligand 1) together with 
CSPG4, MSLN & EGFR. This would in the future allow to identify the groups of patients 
positively responding to e.g. a CSPG4-specific immunotherapy.  
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Figure 10.  SNAP fusion protein conjugated to Alexa488 mechanism of action. 1) The Protein-Fluorophore conjugate 
molecule is in the extracellular environment. 2) Protein-Fluorophore attaches to the specific cancer cell and accumulate on 
the surface of the cell. 3) The Protein-Fluorophore molecule will be internalized.  
 
1.4.1 Main goals/overall objectives of this study: 
1. To evaluate different antibody formats to improve the diagnostic potential of SNAP-
tag based antibody fusion proteins 
To obtain this goal, this will include the following objectives: 
 
• The design of an appropriate vector system for expression of recombinant SNAP-tag 
fusion proteins targeting CSPG4, MSLN & EGFR. 
• Cloning of the open reading frames (ORFs) into the vector system. 
• Transfection of constructs into HEK293T mammalian cells for the expression and 
monitor transfection efficiency by the amount of eGFP positive cells. 
• Harvesting of recombinant proteins from the supernatant of cell culture. 
• Purification of the recombinant proteins by immobilized metal affinity chromatography 
(IMAC) using an ÄKTA avant protein purification system. 
• Analysis by SDS & western blot to confirm expression and purification. 
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Chapter 2: Materials & Method 
2.1  Chemicals, consumables, equipment and suppliers 
All chemicals and kits used in this study were obtained from the following suppliers: 
Thermofisher Scientific (Waltham, USA), Qiagen (Hilden, Germany), Machery-Nagel (Düren, 
Germany), Merck-Sigma (Kenilworth, USA), Integrated DNA Technologies (Coralville, 
USA), GE Healthcare (Little Chalfont, UK), New England Biolabs (Ipswich, USA), BioRad 
(Hercules, USA) and Biochrom (Berlin, Germany).  
The consumables and equipment used in this study were purchased locally from the following 
suppliers: Bio-Smart, Labotec, LasecSA, Separations, Whitehead Scientific, Inqaba Biotec and 
the scientific group. 
The following is a detailed list of all equipment used in the course of the study: 
Equipment Manufacturer/supplier 
• Blue light transilluminator (Dark 
reader DR-89X) 
Clare Chemical 
• BSCII cabinet (Nu5113-400E) NuAire 
• Cell counting chamber (Neubauer) Marienfeld 
• 15 ml / 50 ml Centrifuge (Allegra X-
30R) 
Beckmann-Coulter 
• CO2 incubator (ICO 50med) Memmert 
• CO2 incubator (NU-5800E) NuAire 
• Confocal microscope (LSM-880 
Airyscan) 
Carl Zeiss 
• Electrophoresis system (Mini-
PROTEAN Tetra Cell Mini Trans-
Blot Cell) 
Bio-Rad 
• Electrophoresis system (Sub-Cell 
GT mini & wide-mini) 
Bio-Rad 
• Fluorescent imager (ZOE Cell 
Imager)  
Bio-Rad 
• Flow cytometer (BD LSR II) Becton-Dickinson 
• Gel imaging system (G:BOX 
Chemi-XL) 
Syngene 
Masters Dissertation  Siyabulela Magugu 
 
South African Research Chair in Cancer Biotechnology - 35 - Dec-19 
 
• Heating block (Thermomixer 
Comfort) 
Eppendorf 
• Hot plate & mag’ stirrer (MH-4) Fried Electric 
• Immobilized Metal Affinity 
Chromatography (IMAC) system 
(Avant 25) 
ÄKTA 
• Microcentrifuge (Prism C2500-
230V) 
Labnet 
• Microplate reader, absorbance 
(iMark) 
Bio-Rad 
• Mini Centrifuge (MCF-2360) Laboratory and Medical Supplies 
• Orbital shaker (GyroTwister GX-
1000 3D) 
Labnet 
• Power source for electrophoresis 
(PowerPacTM HC) 
Bio-Rad 
• Shaking incubator (IncoShake 353) Labotec 
• SpeedVac dryer (miVAC DNA-
23050-L00) 
SP Scientific 
• Spectrophotometer (DS-11) DeNovix 
• Vortex mixer (Harmony Usuzio 
VTX-3000L) 
Laboratory & Medical Supplies 





2.2 In silico Vector Design and Vector Cloning 
The in-silico cloning was performed using SNAPgene® (version 3.1.1, GSL Biotech, Chicago) 
to design an open reading frame (ORF) encoding for the recombinant fusion proteins. A 
αCSPG4 (scFv), αEGFR (scFv & VHH), αMesothelin (scFv & VHH) and SNAP-tag were 
designed. An order was then placed to Genscript (New Jersey, USA) for the synthesis of the 
specified open reading frame (ORF). The ORF was provided in a pUC57 commercial vector 
and would later be cloned into the pCB vector (a modified ThermoFischer Elements expression 
vector). The ThermoFischer Elements expression vector was modified by removing C-terminal 
histidines and myc tags near the C-terminal EcoRI, as well as the introduction of N-terminal 
His tags and Enterokinases. The final constructs, designated pCB-αCSPG4(scFv)-SNAP, pCB-
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αMSLN (scFv & VHH)-SNAP and pCB-αEGFR (scFv & VHH)-SNAP was transfected into 
mammalian cells, which secrete the recombinant proteins into the supernatant where it can be 
harvested after visualization of the GFP with transillumination. The pCB-αCSPG4(scFv)-
SNAP, pCB-αMSLN(scFv)-SNAP & pCB-αEGFR(scFv)-SNAP constructs had already been 
verified by way of sequencing and was provided by colleagues and stored in the lab collection. 
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2.3 Molecular Cloning 
2.3.1  Restriction Enzyme (RE) Digestion 
Restriction enzyme digestion was used to generate compatible DNA ends that can be ligated 
together. This means using REs to excise a desired gene of interest in preparation for ligation 
into a designated plasmid. In this case, the process began by making bulk preparations of both 
the commercial pUC57 vector carrying the gene of interest, and the destination vector in use 
by the lab, pCB-AnnexinV-SNAP using the NucleoBond® midi prep kit obtained from 
Machery-Nagel, Germany (#740573). The purpose of this was to increase the quantity of DNA 
for long term storage as well as for molecular cloning related work. It must be noted that for 
the VHH constructs, a modified pCB plasmid housing the SNAP-F variant instead of SNAP 
was used. The digestion reaction was as described in Table 2 below.  
 
Table 2. Components of a restriction enzyme digestion. The illustration shows a 50 ul overnight digest with the various 
components and their volumes. The volumes of enzymes and nuclease free water are variable depending on the type of digest 
i.e. single or double digest. 
Component Final concentration Volume 
DNA 2 µg Adjusted for 
10× NEB CutSmart Buffer 1× NEB CutSmart Buffer 5 µl  
SfiI 2000 U/ml 0.5 µl 
NotI 2000 U/ml 0.5 µl 
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The digest was then left overnight at 37oC for approximately 16-18h. SfiI and NotI restriction 
enzymes or cutting enzymes, obtained from New England Biolabs (NEB) Ipswich, USA, were 
used to excise the gene(s) of interest from the pUC57 vector as well as the AnnexinV from the 
pCB vector. This was done with the intention to ligate the genes of interest from pUC57 vector 
into the pCB backbone. The expected final products would be pCB-αEGFR(VHH)-SNAPF 
and pCB-αMSLN(VHH)-SNAPF.  
 
Materials needed:  
• NucleoBond plasmid purification kit 
• Bacterial culture (Luria Broth) 
• Centrifuge 
• Microcentrifuge 
• 50mL centrifuge tubes 
• 1.5mL centrifuge tubes 
• 70% Ethanol 
• Isopropanol 
• Pipette and tips 
• SpeedVac 
• Sterile deionised H20 (prewarmed to 50
oC) 
• Spectrophotometer (e.g. Nanodrop) 
• 50% Glycerol 
 
Table 3. Reagents & buffers for restriction enzyme digest 
 Composition 
Luria Broth Bacterial culture (1L, pH 
7.0) 
• 7.5g LB agar 
• 5g Tryptone 
• 5g NaCl 
• 2.5g yeast extract 
50% Glycerol (100 ml) • 50ml 100% Glycerol 
• 50ml Sterile water 
70% Ethanol (1L) • 700ml Pure ethanol 
• 300ml Sterile water 
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2.3.2 Agarose Gel Electrophoresis & Gel Extraction 
Agarose gel electrophoresis serves as a tool that is useful in analysing DNA fragments after 
RE digestion. An electric current is applied to separate the fragments by size and nucleic acid 
stain allows for visualization of fragments upon blue light excitation. Gel preparation was 
subject to the size of the gel required. On average, 1.2 and 1.5% agarose gels were made for 
the digested backbone and genes of interest. This required weighing 1.2g & 1.5g of agarose 
powder mixed in 100ml of 1× TAE buffer solution (chemicals for buffer purchased from 
Merck-Sigma, USA) and 1:10 000 dilution of SYBR™ safe DNA gel stain obtained from 
Thermofisher, USA. The solution was heated to boiling temperature, left to cool for 5-10min 
and poured into a gel casting tray with the correct comb size and allowed to solidify. The 
casting tray was then put into a BioRad flat buffer tank filled with 1× TAE buffer. The tank 
was connected to the BioRad PowerPac™ by positive and negative terminals and a voltage of 
120V was applied over  30-60 min to allow the DNA to travel down the gel. DNA bands were 
visualized with blue light (400-495nm) and their sizes were compared against the QuickLoad® 
1 kilobase (kb) and 100 base pair DNA ladders obtained from NEB. The band sizes that we 
expected to see are described in Table 4. 
Table 4. Sizes of plasmids and genes of interest to be used for cloning.  




8233  6564 1669 
pUC57-αMSLN(VHH) 3094 2710 384 
pUC57-αEGFR(VHH) 3100 2710 390 
 
The bands of interest were the pCB backbone and the MSLN & EGFR inserts. After the correct 
bands were visualized at the theoretical sizes described in Table 4, they were excised from the 
gel using a scalpel and the DNA was extracted from the gel by use of the QIAquick Extraction 
kit obtained from Qiagen, Germany (#28704). After the gel was excised it was weighed in an 
Eppendorf tube and thereafter 3 volumes of Buffer QG were added to 1 volume of DNA. The 
yellow colour of the buffer indicates a pH <7.5 because DNA adsorption to the membrane is 
most efficient at this pH. The solution was then incubated at 50oC for 10mins to allow melting 
of the agarose gel and was vortexed thoroughly in 2-5 min intervals. Thereafter one gel-volume 
of isopropanol was added, and the solution was transferred to a QIAquick column and 
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centrifuged (13 000rpm). Buffer QG was added and the solution was centrifuged once more in 
the column. We then washed the DNA in the column with Buffer PE. This buffer assists in the 
removal of excess salts from the DNA. We then transferred the column to a 1.5ml 
microcentrifuge tube and eluted with nuclease free water and centrifuged. The purity of the 
DNA was quantified using the Denovix® Nanodrop spectrophotometer.  
 
Materials needed:  
• Agarose powder 
• 1× TAE buffer 
• SYBRsafe 
• 250mL beaker 
• Microwave 
• Scale, spoon and weigh boat 
• Deionised water 
• Buffer tank 
• Gel tray 
• Comb 
• 6× gel loading dye purple 
• Pipette and tips 
• 1kb and/or 100bp+ DNA ladder 
• Blue light box/ UV gel documentation system 
Table 5. Reagents & buffers for agarose gel electrophoresis 
 Composition 
Agarose gel (1.5%) • 1.5g Agarose powder 
• 100ml  1× TAE Buffer 
• 1:10000 SYBR Safe (after boiling) 
10×TAE Buffer (1L) • 48.5g Tris-base 
• 11.4ml glacial acetic acid 
• 20ml 0.5M EDTA (pH 8.00) 
• Deionised water (top up to 1L) 
1× TAE Buffer (1L) • 100ml 10× TAE Buffer 
• 900ml Deionised water 
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2.3.3 T4 DNA Ligation & Bacterial Transformation 
Ligation is the process of covalently joining two linear fragments of DNA, more specifically, 
forming a phosphodiester bond between the 3’ hydroxyl of one fragment with the 5’ phosphate 
end of another. To ensure successful ligation, we chose a 1:3 ligation ratio (1-part DNA and 3-
parts backbone) which was calculated for on a weight to mol basis using the Promega online 
calculation tool  (https://worldwide.promega.com/resources/tools/biomath/). The vector size 
(7272 bp), concentration (22 ng/ul) as well as the insert DNA size (376 bp) and concentration 
(4.9 ng/ul) were put into the online calculator and the ligation ratios were calculated for. A 1:1 
ratio would require 3ng of insert DNA and this was the basis we used to calculate the 
requirements for the other ratios. 20ul ligation reactions were set up in 1.5 ml tubes as shown 
in the table 6 below. 
 
Table 6. The reagents required to perform a ligation and their volumes. 
Reagent Reaction control 1:3 1:5 
10× T4 DNA Ligase 
Buffer  
2ul 2ul 2ul 
pCB vector (50ng) 2.27ul 2.27ul 2.27ul 
αEGFR(VHH)  0ul 1.8ul (9ng) 3ul (15ng) 
T4 DNA ligase  1ul 1ul 1ul 
Nuclease free water  Make up to 20ul Make up to 20ul Make up to 20ul 
 
The ligase enzyme, obtained from NEB, is responsible for joining the insert DNA with the 
backbone. This method was followed for the αEGFR(VHH) and αMSLN(VHH). Vector only 
and vector with ligase served as the negative controls. The reactions incubated at 16oC 
overnight. Prior to transformation, NEB DH5α competent E. coli cells (strain K12, with 
mutations dlacZ ΔM15 Δ(lacZYA-argF) U169 recA1 endA1 hsdR17 (rK-mK+) supE44 thi-1 
gyrA96 relA1) were thawed on ice. A volume of 5ul of DNA was added to 25ul of bacterial 
cells and incubated on ice for 5mins. The cells were then subject to heat shock (at X °C) for 60 
seconds, altering the bacterial membrane fluidity resulting pore formation allowing for DNA 
entry into the cell. Thereafter, the cells were then chilled on ice for 5min before cold Super 
Optimal broth with Catabolite repression (SOC) medium was added. This is rich medium that 
aids in the recovery of competent cells and maximizes the transformation efficiency. The 
solutions were then mixed thoroughly and 200µl of cells was removed and streaked onto agar 
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plates supplemented with ampicillin and incubated overnight at 37oC. Single colonies were 
then selected, grown in 2ml of Luria Broth agar with an appropriate amount of ampicillin and 
incubated overnight in a shaking incubator. 
 
Materials needed:  
• LB agar powder 
• Distilled H20 
• Ampicillin 
• 1L flask 
• Petri dishes 
• Autoclave 
• T4 DNA Ligase kit 
• 1.5 microcentrifuge tubes 
• Ice 
• Insert DNA 
• Vector DNA 
• Nuclease-free H20 
• Calcium competent E. coli cells (DH5-α) 
• Pipettes and tips 
• Room temperature Super Optimal Broth with Catabolite repression (SOC)  
• Luria Bertani Broth (LB) 
• Incubator with shaker 
• Zyppy Miniprep materials 
• Restriction Mapping materials 
• NucleoBond Midiprep Plasmid Purification materials 
• Sequencing materials 
Table 7. Reagents & buffers for DNA ligation & transformation 
 Composition 
LB Agar plates (20ml per plate) • 35g LB agar powder 
• Deionised water (1L) 
Ampicillin [100mg/ml] • 1g Ampicillin powder 
• Sterile deionised water (1L) 
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2.3.4  Zyppy™ Plasmid Miniprep and Inqaba Sequencing 
The Zyppy™ plasmid miniprep kit was obtained from Zymo Research, USA (#D4036). This 
kit that introduces a pellet-free alkaline lysis method that bypasses the traditional plasmid 
preparation methods that include bacterial culture centrifugation and resuspension steps needed 
to efficiently separate plasmid DNA from E. coli. Alternatively, the alkaline lysis method 
which makes use of homemade buffers and multiple centrifugation steps could have been used. 
The steps described in the Zymosearch Zyppy™ plasmid miniprep protocol were followed 
according to the manufacturer’s instruction. After this protocol, purified plasmid DNA i.e. 
pCB-αEGFR(VHH)-SNAPF and pCB-αMSLN(VHH)-SNAPF were expected. To confirm 
these constructs as being correct, the DNA was diluted in Eppendorf tubes and sent for gene 
sequencing by Inqaba Biotech™ (South Africa). The method of sequencing employed is 
Sanger sequencing, which is a process that involves the addition of chain-terminating 
dideoxynucleotides by DNA polymerase during DNA replication [199]. 
 
Materials needed: 
• 1.5ml microcentrifuge tube 
• 7× Lysis buffer (blue) 
• Neutralization buffer (Yellow) -From fridge 
• Collection tubes and Zymo-Spin IIN column 
• Endo-wash buffer 
• Zyppy wash buffer 
• Molecular biology grade water (pre-heated at 50˚C) 
• Microcentrifuge 
 
2.4  Expression of SNAP fusion proteins in tissue culture, flow cytometry and protein 
purification by AKTA Avant system 
Transfection is the process of introducing DNA into a mammalian cell that eventually results 
in protein expression using the cells machinery. To transfect the constructs, the X-tremeGENE 
transfection reagent (obtained from Sigma-Aldrich, USA) and protocol were used. The reagent 
includes a blend of lipids and other components that can complex to DNA, allowing for the 
uptake of DNA by the mammalian cells and transient expression of proteins by the cells with 
minimal toxicity and changes in morphology. Mammalian transfection was performed in the 
HEK293T cell line derived from HEK293 cells. HEK293T cells were seeded at 70-90% 
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confluency into 2 x 2 mm round cell culture vessels 48 hours prior to the experiment. The cells 
were then combined with plasmid DNA, RPMI (Roswell Park Memorial Institute) medium 
supplemented with 10% heat inactivated fetal bovine serum and 100U/ml penicillin (#P3032 
Sigma, USA) and 100μg/ml streptomycin (#S-91370 1105 Sigma, USA), as well as the X-
tremeGENE HP DNA Transfection Reagent in a microcentrifuge tube at a 3:1 ratio (v/v) of 
reagent to DNA. The mixture will be evenly distributed amongst cells and incubated at 37oC 
in 5% CO2 before applying selective Zeocin™ (Thermofisher, USA) pressure (10% v/v).  The 
zeocin pressure was applied until the cultures were dominated by EGFP expressing cells (~3-
4 weeks). The tissue culture and EGFP images were taken with the ZOE™ Flourescent Cell 
Imager under brightfield and green line. After selection pressure, the percentage EGFP 
expression was determined by flow cytometry. 5 x 104 cells were counted by staining with 
Trypan blue (1:1 volume ratio) and the BioRad automated cell counter. The cells were placed 
in 15ml falcon tubes and centrifuged @ 1500 x g for 5mins. The cells were then resuspended 
in 1× phosphate buffered saline (PBS) solution and transferred to FACS tubes (BD). The cells 
were fixed with 200ul of 2% paraformaldehyde (PFA), centrifuged again and resuspended in 
FACS buffer. After a sufficient period of time, where transfected cells showed adequate EGFP 
expression, cell culture supernatant (CCSN) was be collected for purification using the AKTA 
Avant system. Proteins were harvested by collecting the CCSN from T175 culture flasks into 
a 50mL sterile plastic tube and centrifuged it at 1000 × g for 5mins. The tubes were stored at 
4oC in preparation for protein purification. The purification process was performed using ion 
metal affinity chromatography (IMAC), which makes use of the high affinity of Ni2+ for poly-
His tags. The 6× His tag confers strong binding of the proteins to Ni2+ rich column ensuring 
that they do not get washed out of the resin while unbound proteins are removed. The AKTA 
system will delivered purified proteins in fractions displayed as peaks on a graph where the 
protein of interest was fractionated. These fractions were concentrated using Amicon® filters 
obtained from Sigma-Aldrich. Manufacturers protocols were followed for the Amicon® Ultra 
15ml Centrifugal Filters (10,000 MWCO), which filters out proteins of 10kDa and below, in a 
centrifuge with a swinging-bucket rotor. A maximum volume of 15ml could be centrifuged (@ 
4000 x g) at a time. The flow through was then discarded and the remaining concentrated 
protein was transferred to a 1.5mL Eppendorf tube. The concentrated SNAP-tag proteins can 
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Materials needed: 
•  AKTA Avant 
•  5ml HisTrapTM excel [ GE Healthcare: Lot # 10264409]  
•  Incubation[4x], equilibration & elution buffers* Cell culture supernatant (CCSN) 
•  96 deep well plate square V-bottom [Lasec-Lot # 18041] 
•  0.45um PVDF membrane (47 mm) [Sigma: Lot # R8EA65403] 
•  Amicon Ultra-15 filters (10kDa) [Sigma: Lot # R8MA11064] 
 
Table 8. Reagents & buffers for expression & purification of SNAP-tag proteins 
 Composition 
4X Incubation buffer (pH 8.00) • 24g NaH2PO4 [200mM] 
• 7.13g NaCl [1.2M] 
• 2.72 Imidazole [40mM] 
• Deionised water (top up to 1L) 
Equilibration buffer (pH 8.00) • 6g NaH2PO4 [50mM] 
• 17.53 NaCl [300mM] 
• Deionised water (top up to 1L) 
Elution buffer (pH 8.00) • 6g NaH2PO4 [50mM] 
• 17.53 NaCl [300mM] 
• 17.02g Imidazole [250mM] 
• Deionised water (top up to 1L) 
10× PBS • 17.8 g of Na2HPO4 [100mM] 
• 2.4 g of KH2PO [18mM] 
• 80 g of NaCl [1.37M] 
• 2 g of KCl [27mM] 
• Sterile deionised water (top up to 1L) 
1× PBS • 100ml 10× PBS 
• 900ml sterile deionised water 
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2.5 SDS-PAGE and Western blot analysis 
Expression and purification of SNAP fusion proteins was assessed by sodium dodecyl sulfate–
polyacrylamide gel electrophoresis (SDS-PAGE) and western blotting. Polyacrylamide gel 
(10% Resolving, 4% Stacking) electrophoresis (with SDS for reducing conditions) allows 
analysis of protein samples by size on a gel by electrophoresis and by immunoblotting using 
anti-His antibodies. The proteins are separated according to size by electrophoresis. 
Visualization of the protein bands is achieved by using the using AcquaStain (Bulldog Bio, 
UK) and thereafter they are analysed against the PageRuler pre-stained protein ladder obtained 
from Thermofisher (#26616). Alternatively, for the detection of the fusion protein the western 
blotting technique was used. The western blots were performed by initially transferring the 
proteins onto a PVDF transfer membrane that was obtained from Roche, Switzerland 
(#03010040001). The membranes were then incubated at 4oC overnight with an anti-conjugate 
protein or anti-His tag antibodies obtained from Cell Signalling Technologies (Danvers, USA). 
A secondary antibody, Goat-Anti-Rabbit-HRP that was obtained from Bio-Rad (Hercules, 
USA), was then added resulting in an enzyme substrate reaction. The membrane was thereafter 
treated with a chemiluminescence detection agent i.e. WesternBrightTM ECL detection kit 
(manufactured by Advansta, USA) and presented on an X-ray film. If positive results are 
obtained i.e. specific bands form, the study would have engineered monospecific recombinant 
proteins. Following the above-mentioned analyses, application studies  in CSPG4, EGFR & 
MSLN + TNBC cell lines were performed.  
 
Materials needed: 
• Glass plates & combs 
• Casting stands & frames 
• Buffer tank 
• Running & transfer electrode modules 
• Running & transfer (cold) buffers 
• Gel ingredients 
• Protein samples 
• 4× loading dye 
• Protein ladder 
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Table 9. Reagents & buffers used for SDS & Western Blot 
 Composition 
10× Running buffer • 30g Tris 
• 10g SDS 
• 144g Glycine 
• Deionised water (top up to 1L) 
1× Running buffer • 100ml 10X Running buffer 
• 900ml deionised water 
10× Transfer buffer • 30g Tris 
• 144g Glycine 
1× Transfer buffer (cold) • 100ml 10× Transfer buffer 
• 200ml Methanol (100%) 
• 700ml deionised water 
10% SDS • 10g SDS 
• 100ml deionised water 
10% Ammonium per sulfate (APS)  • 5g Ammonium per sulfate 
• 50ml  
10× Tris-buffered saline (TBS), (pH 
7.6/8.8/6.8) 
• 24 g of Tris Base [200mM] 
• 88 g of NaCl [1500mM] 
• Deionised water (top up to 1L) 
1× Tris-buffered saline, 0.1% (w/v) 
Tween® 20 (TBST) 
• 100ml 10× TBS 
• 900ml deionised water 
• 1ml Tween® 20 
 
2.6 Protein Quantification by Spectrophotometry  
Spectrophotometry makes use of a machine that can register how much light is absorbed by a 
substance at a set wavelength and quantify this value in terms of concentration.  The Denovix® 
DS-11 spectrophotometer which has the capacity to quantify microvolumes of DNA, proteins 
and labelled proteins was used. DNA is absorbed at wavelength of 260 nanometres (nm) and 
proteins are absorbed at a wavelength of 280 nm. To measure the protein concentration, it is 
required to compute the theoretical molecular weight (MW) and extinction coefficient (ε) of 
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the protein. These details were obtained using the Expasy online tool 
(https://web.expasy.org/protparam) and read as seen in the table below. 
 
Table 10. The theoretical molecular weights and extinction coefficients of the proteins of interest. 
Protein Molecular Weight (M-1 
cm-1) 
Extinction coefficient (ε) 
αEGFR(VHH)-SNAPF 38217.31 59150 
αEGFR(scFv)-SNAP 503345.64 77725 
αCSPG4(scFv)-SNAP 51154.63 77725 
αMSLN(scFv)-SNAP 51106.45 87695 
 
Materials needed: 
• Protein samples 
• Appropriate blanks (MiliQ water, PBS) 
• P10 pipette 
 
2.7  Binding analysis in CSPG4, EGFR & MSLN+ tumour cell lines using confocal 
microscopy 
To confirm the functionality of the protein we will test its binding on tumor cell lines. The main 
cell lines tested on were MDA-MB-231 (ATCC: HTB-26), Hs578t (ATCC: HTB-126) and 
MDA-MB-468 (ATCC: HTB-132) which are TNBC tumor cell lines that are known to express 
CSPG4, MSLN and EGFR on their surfaces. It must be noted that not all tumor cell lines 
express each receptor on their surfaces and will serve as  negative controls alongside another 
cell line included in the study, A2058 (ATCC: CRL-11147) used as a negative control for 
αEGFR(VHH)-SNAPF and αEGFR(scFv)-SNAP. Binding analyses on these tumor cells were 
visualized using confocal microscopy. We used the 880 Airyscan confocal microscope making 
use of the Argon laser at 488nm to view the green fluorescence and 405nm DAPI laser to view 
Hoechst stained cell nuclei. 5 x 104 cells were counted by staining with Trypan blue (1:1 
volume ratio) and the Bio-Rad automated cell counter. The cells were transferred to single-
well live cell culture dishes and stained with  250uM of labelled protein and incubated for 
30mins followed by two washes with serum-free media (SFM). The cells were then stained 
with Hoechst (1:1000) for 5-10min, washed twice with SFM and left in 200ul of SFM at room 
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temperature for imaging. The conjugation reaction between SNAP fusion proteins with BG-
Alexa Fluor 488, received from NEB, was performed as follows:  
 
Table 11. The reaction set up for conjugation between SNAP-tag  fusion proteins and SNAP-tag substrates. 
Component Volume Final Concentration 
Phosphate Buffered Saline 
(PBS) 
42ul 1× 
50mM Dithiothreitol (DTT) 1ul 1mM 
50uM SNAP-tag Purified 
Protein 
5ul 5uM 
250uM SNAP-tag substrate 2ul 10uM 
 
The conjugation efficiencies were calculated by measuring the approximate concentrations of 
unlabeled and labelled protein using spectrophotometry and thereafter determining the 
percentage labeling: 
 
% 𝑝𝑟𝑜𝑡𝑒𝑖𝑛 𝑐𝑜𝑛𝑗𝑢𝑔𝑎𝑡𝑖𝑜𝑛 =
[Labelled protein]
[Unlabeled protein]
 x 100 
 
The labelled proteins were then prepared for binding studies on tumor cell lines positive for 
the receptor targets. 3 x 104 cells were seeded into live culture dishes and grown in Dulbecco’s 
Modified Eagles Medium (DMEM) supplemented with 10% (v/v) Fetal Bovine Serum (FBS, 
obtained from ThermoFisher Scientific) and 1% Penicillin Streptomycin (PenStrep, obtained 
from Sigma-Aldrich). The only exception in the TNBC cell lines was MCF-7 as it was 
previously grown in RPMI media and we followed suit. 
 
Materials needed: 
•  BG-modified Alexa488 substrate 
•  SNAP fusion protein 
•  Live cell viewing dishes 
• Tissue culture reagents 
• Tumour cell lines  
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Table 12. Reagents & Buffers for binding analyses 
 Composition 
10× PBS • See above 
1× PBS • See above 
50 mM DTT • 7.7mg DTT powder 
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Chapter 3: Results 
This study aimed to generate novel molecules in the form of SNAP-tag fusion molecules aimed 
at improving immunodiagnostic and immunotherapeutic agents for the validation and treatment 
of TNBCs. The molecules were initially designed by way of in-silico cloning. The molecule 
was designed to contain a targeting domain (scFv/VHH) and a domain that can attach BG-
residues (SNAP-tag). Thereafter the molecules underwent molecular cloning which consists of 
performing restriction enzyme digestion, agarose gel electrophoresis, DNA ligation and Sanger 
sequencing by Inqaba Biotec. The processes that followed after confirmation of DNA after 
sequencing involved transfection of the DNA into a mammalian vector expression system and 
harvesting of transiently expressed proteins. These proteins were then purified using IMAC 
and thereafter confirmed using SDS PAGE and Western Blotting. The confirmed SNAP-fusion 
proteins were then conjugated to a BG-modified fluorophore in Alexa-488 and binding studies 
performed on receptor positive tumour cell lines (visualized by confocal microscopy). 
 
3.1 in-silico Cloning using SNAP-gene software 
  
A B 
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Figure 11. Schematic diagrams of pCB plasmid housing our opening reading frames (ORFs). Panels A & B show the full 
plasmid architecture for pCB-αEGFR(scFv)-SNAP and pCB-αEGFR(VHH)-SNAPF. Panels C & D show the full plasmid architecture 
for pCB-αMSLN(scFv)-SNAP and pCB-αMSLN(VHH)-SNAPF. Panel E shows the full plasmid architecture for pCB-αCSPG4-SNAP. 
 
The software SNAP-gene was used as the in-silico tool to confirm the antibody genes ordered 
from Genscript (Fig. 11). In-silico cloning allowed for the confirmation of the CDR regions, 
ensures correct assembly of the ORFs into the pCB plasmid and correctly annotating the 
features of the plasmid. In-silico cloning is also an important tool in providing theoretical 
C D 
E 
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sequences for analysis against sequences provided after sequencing by Inqaba. The plasmid 
vector pCB houses the recombinant ORF containing the sequence of the recombinant proteins 
αCSPG4(scFv)-SNAP, αMSLN(scFv)-SNAP, αMSLN(VHH)-SNAPF and αEGFR(scFv)-
SNAP and αEGFR(VHH)-SNAPF which were cloned out of a commercial pUC57 vector. The 
plasmid also contains the sequences of SNAP-tag or SNAP-F which are important for binding 
BG-substrates. The plasmid also houses an Ampicillin resistance gene that allows for selection 
of bacterial colonies successfully transformed with plasmid DNA on agar plates supplemented 
with the antibiotic ampicillin. The purified plasmid DNA was eventually transfected into a 
mammalian expression system in HEK293T cells. The plasmid also contains the gene for the 
EGFP which is a readily detectable marker under light fluorescence using the ZOE Fluorescent 
Cell Imaging (BioRad, South Africa) which is equipment that uses three fluorescent channels 
as well as brightfield for applications in cell culture, and moreover, it uses a simple digital 
viewing system that differs from traditional fluorescent microscopes and can be used by 
researchers without extensive experience with fluorescence. The plasmid has also been fitted 
with a Zeocin/Bleomycin resistant gene that allows for the selection of HEK cells successfully 
transfected with the plasmid DNA. The gene allows for the enrichment of cultures, ensuring 
that there are only successfully transfected cells in culture as seen by EGFP expression.  The 
Ig kappa (Igκ) leader sequence is important because it plays a role as a signal sequence that 
allows for the secretion of protein into the supernatant. The poly-histidine tag is important for 
affinity purification of proteins and protein confirmation through western blotting. The plasmid 
was also equipped with numerous restriction sites, such as SfiI and NotI, that would allow for 
molecular cloning experiments such as restriction enzyme digestion. 
3.2 Molecular Cloning  
Molecular cloning refers to different experiment that are performed as a collective with the 
intent to amplify a particular DNA fragment using a host organism [200]. The cloning 
strategy employed involved restriction enzyme digestion of the commercial vector housing 
the ordered genes of interest and the pCB vector in preparation for the ligation of the two 
with T4 DNA ligase. The sequence of the ligated product was then confirmed by sequencing 
by Inqaba Biotec and restriction enzyme mapping prior to its transfection into mammalian 
cells in tissue culture. 
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3.2.1 Restriction enzyme digestion and Gel electrophoresis 
Restriction enzyme digestion is the process of using restriction enzymes to excise a DNA 
fragment from a plasmid for DNA analysis or leaving sticky-ends on the digested plasmids in 
preparation for ligation with a suitable DNA fragment. The use of SfiI and NotI restriction 
enzymes allowed for the cloning of the genes of interest i.e. αCSPG4(scFv), αMSLN(scFv), 
αMSLN(VHH), αEGFR(scFv) and αEGFR(VHH) by exposing sticky ends on the plasmids to 
be ligated with ORFs. This processes also allows for the correct cloning of products in 
preparation for sequencing by Inqaba Biotec. Performing a gel electrophoresis allows for the 
visualization of fragments of DNA under UV or blue light as shown in Figure 12. The following 
result is for αEGFR(VHH) only and will exemplify the successful molecular cloning of 
plasmids containing the scFv (αEGFR, αMSLN and αCSPG4) genes provided by colleagues. 
The plasmids containing the scFv genes were already transfected into a transient expression 
system and these results are expanded up in Chapter 3.3. Indicated by the orange rectangle are 
the double digests in which we expected to see the αEGFR(VHH) bands at a size of ~370 bp 
of the as well as the pUC57 vector of ~2.7kb higher up on the gel. Although the bands were 
feint, their appearance of the gel gave researchers confidence that this was the gene of interest 
as it aligned to the correct region according to the 100 bp Quickload ladder. The single digest 
and undigested controls were slightly above the digested vector. This result was expected as 
the controls were not fully digested or digested at all, and a shift in vector size would be 
unexpected. The highlighted gel bands were then excised, pooled together into one tube and 
processed according to set protocols in preparation for ligation. No successful digestion was 
recorded for αMSLN(VHH). 
   
Figure 12. A 1.5%  Agarose gel depicting bands after RE digest. Lanes 1-3 represent the double digests of the commercial 
pUC57 vector housing the αEGFR(VHH) gene (~370bp) with SfiI and NotI restriction enzymes. Lanes 4 and 5 represent single 






1 2 3 4 5 6 7 8 
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3.2.2 T4 DNA Ligase & Bacterial transformation 
DNA ligation is the act of combining two DNA molecules using the DNA ligase enzyme. The 
enzyme forms phosphodiester bonds between 3’ hydroxyl group and the 5’ phosphate group 
on nucleotides [201]. The ligated products (the ORFs and the pCB vector) were transformed 
into DH5-α E. coli cells. The growth of colonies for the designated constructs as seen in Figure 
13, shows successful ligation of the plasmid and its successful transformation into the E. coli. 
Positive colony growth was seen on the ampicillin supplemented plates suggesting a successful 
transformations in both the 1:3 and 1:5 plasmid vector to DNA insert ratios. The digested vector 
only control showed no growth as expected. A vector with ligase control (no insert) to test for 
religation of the plasmid was not included. A successful ligation was noted at the lowest vector 
to DNA ratio, and these transformants were selcted for subsequent expeirments. Positive 
colonies selected from the 1:3 ligation plate, which showed a transformation efficiency of 57.2 
x 103 CFU/ug, were regrown and in Luria Bertani Broth (LB), the plasmids purified and 
prepped for restriction mapping and sequencing by Inqaba™ Biotech. 
A. Vector only control B. 1:3 ligation  C. 1:5 ligation 
  
 
Figure 13. Cultured DH5-alpha competent E. coli cells on agar plates supplemented with ampicillin after T4 DNA ligation 
reaction. A) The plasmid vector digested with restriction enzyme was plated without the addition of T4 DNA Ligase enzyme. 
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3.2.3 Sanger sequencing by Inqaba™ , Alignments & RE Mapping 
DNA sequencing allows the determination of a specific order of nucleotide bases in a DNA 
molecule. Inqaba™ Biotech makes use of tailor-made sequencing methods which may 
sequence single reactions or whole genome sequences. The returning sequences for the 
experimental constructs were aligned using SNAPgene, and compared to the sequences that 
were generated in silico. Forward and reverse primers that bind to different parts of the plasmid 
were designed to assess the nucleotide sequence of the ORFs as seen by the red arrows in 
Figure 14. The nucleotide base sequences showed 100% identitiy and no signs of missing or 
altered bases. The plasmid was then prepared according to set protocols and transfected in 
HEK293T cells.  
 
Figure 14. Sequencing of pCB-αEGFR(VHH)-SNAPF by Inqaba Biotec. Snap-gene software was used to align the sequences 
returned to us from sequencing by Inqaba. The red arrows are illustrative of forward and reverse primers that were 
complimentary to various areas of our ORF and mapped out these regions.  
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Restriction enzyme mapping is a method that is used to confirm successful ligation of the gene 
of interest into a plasmid. A cocktail of restriction enzymes was used and the banding pattern 
visualized on an agarose gel can be compared to the theorectical gel pattern simulated using 
SNAPgene software. The gel pattern in Figure 15B. matched  with the theoretical pattern from 
the simulated gel (Fig. 15A).  The plasmid was then transfected into HEK293T cells in tissue 
culture for transient protein expression. 
 
3.3 Tissue Culture & Protein profiling 
The mammalian expression system of choice is HEK293T cells. These cells have been stably 
transformed with the SV40 large T-antigen which binds to SV40 promoter site present in the 
plasmid architecture to allow for the expression of our recombinant proteins. The proteins will 
be transiently expressed and harvested from the CCSN. The proteins that will be produced are 
scFv (CSPG4, MSLN & EGFR) and VHH (EGFR) molecules recombinantly fused to SNAP-
tag or SNAP-F. 







Figure 15. Restriction enzyme mapping of pCB-αEGFR(VHH)-SNAPF by Restriction Enzyme digestion. 15A) An 
image showing the restriction mapping simulation as performed by a gel electrophoresis function on the Snap-gene 
software. 15B) A 1.5% agarose gel with DNA bands of pCB-EGFR(VHH)-SNAP digested with either PvuII only or PvuII 
+ MluI restriction enzymes. Lane 1 shows the 100bp PageRuler ladder, lane 2 is the undigested control, lanes 3 & 5 
show DNA digested with PvuII + MluI, lanes 4 & 6 show DNA digested with PvuII only and lane 7 shows the 1kb 
PageRuler ladder. 
A B 
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Figure 16. Visualization of transfected HEK293T cells under fluorescent cell imaging. The cells were visualized using 
the ZOE Fluorescent Cell Imager under brightfield and the green line 2-7 days post transfection/post-thawing and 
monitored over a 12-week period.  
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Figure 16 A-C show cell growth of HEK293T transfected with the following plasmids: pCB-
αCSPG4(scFv)-SNAP, pCB-αEGFR(scFv)-SNAP, pCB-αMSLN(scFv)-SNAP. These cells 
were stored at -80oC in 10% Dimethyl Sulfoxide (DMSO) and were provided from the lab 
collection.  Only a few cells were growing in the first week after transfection but after several 
medium changes and selection pressure using Zeocin, the cells were more confluent and 
expressing EGFP by week 3. The HEK293T scFv constructs took approximately 12 weeks in 
culture for all cells to express EGFP whereas the cells transfected with the VHH construct 
reached this expression after 5-6 weeks of culturing (Fig. 16). This suggested that this was the 
average amount of time it took for proteins to be produced by the cells and were only ready for 
harvesting after this period. It is possible that the cells responded better to the plasmid with the 
VHH construct as oppose to the scFv constructs. The untransfected HEK293T control showed 
only backgound as expected.  A total volume of 1L of CCSN was harvested  from cells 
expressing the scFv protein and only 500mL was able to be collected for the cell expressing 
the VHH protein. At the point of protein harvest, the cells were analyzed for levels of EGFP 
expressions.  
Upon visual inspection, all the transfected cells were healthy and confluent. The cells 
transfected with αEGFR(VHH)-SNAPf showed the highest fluorescence intensity while the 
cells transfected with αCSPG4(scFv)-SNAP showed the weakest. The αEGFR(scFv)-SNAP 
showed fluorescence intensities comparable to its VHH counterpart but expressed by fewer 
cells and the same comparison can be made for the cells transfected with αMSLN(scFv)-SNAP. 
To quantify these results, we performed flow cytometry to measure percentage EGFP 
expression. 
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The cells were prepared according to set standard protocols optimized for our needs and 
analyzed using the BD Biosciences FACS Caliber flow cytometer. The average EGFP 
expression for αCSPG4(scFv)-SNAP was recorded at 48.4% (Fig. 17A), αMSLN(scFv)-SNAP 
was recorded at 51.56% (Fig. 17B), αEGFR(scFv)-SNAP was recorded at 45.8% (Fig. 17D) 
and αEGFR(VHH)-SNAPF was recorded at 44.3% (Fig. 17C). Interstingly, the VHH construct, 
having been in culture for a considerably less time than the other constructs, showed an EGFP 
Figure 17. Flow cytometry data showing the EGFP expression profiles of transfected HEK293T cells. A) This row represents the EGFP expression 
profile for αCSPG4(scFv)-SNAP (triplicates) and its HEK293T control. B) This row represents the EGFP expression profile for αMSLN(scFv)-SNAP 
(triplicates) and its HEK293T control. C) This row represents the EGFP expression profile for αEGFR(VHH)-SNAPF (triplicates) and its HEK293T control. 
D) This row represents the EGFP expression profile for αEGFR(scFv)-SNAP and its HEK293T control. 
 
HEK293T only control 
HEK293T only control 
HEK293T only control 
HEK293T only control 
αCSPG4(scFv)-SNAP αCSPG4(scFv)-SNAP αCSPG4(scFv)-SNAP 
αMSLN(scFv)-SNAP αMSLN(scFv)-SNAP αMSLN(scFv)-SNAP 
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expression profile comparable to the scFv constructs. Although the cells showed fair EGFP 
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Figure 18. Elution profiles from IMAC purification of proteins. All elutions were gradual from 0-60% and then immediately 
ascends to 100%. The profiles are represented as follows A) αCSPG4(scFv)-SNAP protein, B) αMSLN(scFv)-SNAP protein, C) 
αEGFR(scFv)-SNAP and D) αEGFR(VHH)-SNAPF. 
 
The samples were purified using the AKTA Avant system using IMAC. IMAC allows for 
competitive binding of His-tagged proteins onto a resin of a His-trap column. The elution buffer 
is responsible for initially washing away unbound proteins in the His-trap column and with 
increasing concentrations releases the desired protein in fractions. The protein elution and 
fractionation profile was as shown in Figure 18.  The protein fractions were then concentrated 
using Amicon® filtration. After this process the protein concentration were measured using the 
Denovix spectrophotometer and read as follows:  
Table 13. Protein concentrations after Amicon filtration, measured using spectrophotometry. 
Proteins Protein concentration 
αCSPG4(scFv)-SNAP 1.783 mg/ml 
αMSLN(scFv)-SNAP 5.201 mg/ml 
αEGFR(scFv)-SNAP 3.671 mg/ml 
αEGFR(VHH)-SNAPF 4.803 mg/ml 
The trend noticed in these profiles is two individual peaks per purification. It was initially 
hypothesized that the first peak was represented by contaminating proteins e.g. Bovine Serum 
Albumin (BSA) but upon further investigation it was found that this represented the protein of 
D 
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interest but at a lower concentration to the second peak. This finding suggests that these 
proteins bound poorly to the resin, if at all. As such, all downstream processes were followed 
using the concentrated proteins in the second peak. Interestingly, the αEGFR(VHH)-SNAPF 
showed competitive concentrations to the scFv proteins while only having a volume of 500ml 
of harvested and this may be a positive going forward. 
3.3.2 SDS PAGE & Western Blotting 
An SDS PAGE gel is used to separate proteins by gel elctrophoresis by molecular weight. The 
proteins that would produced were expected to appear in the regions between 48-58 kDa 
acording to the protein ladder (Fig. 19A). The banding patterns visualized, after staining with 
Aquastain dye, for the scFv proteins were in the correct regions for each. Although the proteins 
were purified, the samples showed multiple bands but the most concentrated of each were at 







Figure 19. SDS and Ponceau stained PVDF membrane of proteins after purification with the AKTA Avant system. A) This shows an SDS 
PAGE gel with αCSPG4(scFv)-SNAP, αEGFR(scFv)-SNAP and αMSLN(scFv)-SNAP fusion proteins appearing as dark bands as denoted by the 
red rectangle. The sizes of the proteins were compared against a colorimetric ladder from. B) This shows a PVDF membrane stained with 
Ponceau Red stain. Ponceau S Acid Red is an acid stain that allows for reversible detection of proteins on membranes.  
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The proteins were transferred onto a polyvinylidene fluoride (PVDF) membrane for western 
blotting. The membrane was stained using Ponceau S Acid Red stain, which allows for rapid 
detection of proteins on a variety of membranes whereas Aquastaining can only be used to stain 
SDS gels. In Figure 19B, we were abe to see a banding pattern similar to that of protein of 
interest seen in Figure 19A. Unfortunately, these results could not be replicated by way of 
western blotting but researchers proceeded to test for the functionality of these proteins using 
tumor cell lines expressing the target receptors. 
A positive western blot result was shown after purification of the VHH fusion protein as seen 
in Figure 20. The αEGFR(VHH)-SNAPF proteins appeared as two intense bands at 
approximate 38 kDa, according to the ladder, which was the expected size of the protein. The 
αEGFR(scFv)-SNAP protein served as a control as it had been previously confirmed by a 
colleague Dr. Nsole. The intensity and size of the VHH band suggested that the concentration 
of the SNAP-fusion protein was higher than its scFv counterpart. This is a desirable result as 
the the volume of CCSN collected for purification of the VHH construct was considerably less 
than the scFv constructs which suggests that a higher concentration of protein can be obtained 
with a lower volume with the VHH construct. Upon confirmation of the proteins, the protein 
functionality was tested for by performing conjugations with a fluorophore and testing the 





Figure 20. Western blot membrane image of EGFR(VHH)-SNAPF and EGFR(scFv)-SNAP proteins. The proteins were 
successfully transferred onto the PVDF membrane and tracked using a 1o anti-His antibody and 2o anti-Goat-Rabbit HRP 
antibody for detection of proteins. The first two lanes show the αEGFR(VHH)-SNAPF proteins. The third lane is empty. The 
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3.3.3  Conjuagtion to Alexa 488 and Binding studies in TNBC+ tumor cell lines 
After confirmation of proteins by way of SDS PAGE and western blotting, the proteins were 
conjugated with BG-Alexa Fluor 488. The SNAP-tag binds BG-substrates in a 1:1 
stoichiometry which made this fluorophore a good marker for the functionality of the SNAP-
tag component of the fusion protein. The conjugated proteins were run on an SDS gel and 
exposed to blue light (λ=380-500nm). Alexa Fluor488 is excitable at a wavelength of 488nm 
which falls within the spectrum of blue light. Successful conjugation was observed with all the 
scFv-SNAP and VHH-SNAP fusion proteins (Fig. 21). The unconjugated controls did not 
appear when the gel was exposed to blue light showing that this was true fluorescence from the 
fluorophore. The intensity of flourescence suggests that there are differences in conjugation 
efficiencies between the various proteins.  
The concentrations of both labelled and unlabelled proteins were measured using the Denovix 
spectrophotometer and the conjugation efficiency was calculated for. αCSPG4(scFv)-SNAP 
showed the highest percentage conjugation followed by αEGFR(VHH)-SNAPF, 
αEGFR(scFv)-SNAP and αMSLN-SNAP. It was surprising to find that αMSLN-SNAP showed 
the lowest efficiency of conjugation as it showed the highest concentration of unconjugated 
protein. Although, based on the fluorescent intensities visualized in Fig. 21, these two results 
corroborate with one another. The αEGFR(scFv)-SNAP and αCSPG4(scFv)-SNAP are as 
expected. The αEGFR(VHH)-SNAPF provided a good result as it showed that the SNAPF 
variant is functional and could possibly work better than the original SNAP-tag format based 
on the conjugation efficiencies.  
 
5 6 1 2 3 4 8 7 
Figure 21. SDS gel of proteins conjugated to Alexa488 fluorescing under blue light. The proteins of interest were linearized and run on an SDS gel 
after being conjugated with Alexa488. The SDS gel was put under blue light in order to excite the Alexa488 bound to the proteins. 1, 3, 5 & 7) 
αEGFR(scFv)-SNAP, αCSPG4(scFv)-SNAP, αMSLN(scFv)-SNAP & αEGFR(VHH)-SNAPF bound to Alexa488 respectively. 2, 4, 6 & 8) The unbound controls 
of the afore mentioned proteins. 
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Table 14. The respective concentrations of conjugated and unconjugated proteins, as well as the approximated 
percentage conjugation efficiency. 
Protein Concentration of 
unconjugated 
protein 
Concentration of protein 




αCSPG4(scFv)-SNAP 1.783 mg/ml 1.097 mg/ml 61.53% 
αMSLN(scFv)-SNAP 5.201 mg/ml 1.898 mg/ml 36.5% 
αEGFR(scFv)-SNAP 3.671 mg/ml 1.51 mg/ml 41.13% 
αEGFR(VHH)-SNAPF 4.803 mg/ml 2.625 mg/ml 54.65% 
 
After conjugation of proteins with Alexa 488 and confirmation of the SNAP-tag component of 
the protein, the antibody binding ability of the proteins was tested and viewed using confocal 
microscopy. Figure 22A shows the binding experiment for the αCSPG4(scFv)-SNAP protein. 
There was no binding on the negative control (MB-MDA-468) which is not known to express 
the CSPG4 surface receptor, but a clear surface label was seen on the Hs578t cell line which 
has been reported to express CSPG4. The next image shows binding of the αEGFR(scFv)-
SNAP protein to MB-MDA-468 tumor cell line and no binding on the A2058 negative control 
(Fig. 22B). Although the cells were relatively stressed under the DIC view, a membrane label 
could be seen on the experimental cell line as oppose to the negative control. The binding of 
the EGFR(scFv) fusion protein was mimicked by its VHH counterpart (Fig. 22C). The 
αEGFR(VHH)-SNAPF-Alexa488 showed a bright surface label signal on the experimental cell 
line and no binding was seen on the negative. The bright green signal of this protein suggests 
that the SNAP-F variant does indeed bind BG-substrates better than the original SNAP-tag or 
there was more accumulation of protein on the cell surface as compared to Fig. 22A & B. There 
was partial internalization of this protein as well which suggested that its’ small size may 
contribute to faster intake of protein by the cell. No positive results were recorded for 
αMSLN(scFv)-SNAP due to a lack of tumor cell lines strongly expressing the surface receptor. 
These qualitative results showed the production of full-length functional proteins that could 
potentially be used for future diagnostics and therapeutics for a variety of diseases. 
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DIC No Surface label 
Figure 22. Confocal imaging of tumor cell lines labeled with SNAP-tag proteins conjugated to Alexa 488. The images were taken focusing on surface 
label, nuclear staining with Hoescht and cell morphology with Differential Intereference Contrast (DIC). A) This shows tumor cell lines labeled with 
αCSPG4(scFv)-SNAP-Alexa488. The negative control was the MB-MDA-468 cell line (stained with Hoescht) and the experimental cell line was Hs578t 
(without Hoescht). B) This tumor cell lines labeled with αEGFR(scFv)-SNAP-Alexa488. The negative control was the A2058 cell line (stained with 
Hoescht) and the experimental cell line was MB-MDA-468 (stained with Hoescht). C) This shows tumor cell lines labeled with αEGFR(VHH)-SNAPF-
Alexa488. The negative control and experimental cell lines were the same as in figure 22B. 
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Chapter 4: Discussion & Conclusion 
4.1 Discussion 
TNBC proves to be an issue due to its onset in young premenopausal women, particularly those 
of African descent, in developing and undeveloped countries. Poor prognosis is accompanied 
by low survival rates, a result of its high rates of chromosomal mutations, high division rates, 
mutations in the p53 and BRCA1 genes as well as lymphatic dissemination [202]. This rapid 
progression of the cancer coupled with the lack of adequate treatment strategies further 
complicates things for the medical industry, but this opens avenues for the discovery of novel 
therapeutics against TNBC. In this study, CSPG4 (which is overexpressed in 50% of TNBCs) 
[203], [204], EGFR (which is overexpression in 13-76% of TNBCs) [205]–[208] and MSLN 
(which is overexpressed in 67% of TNBCs) [171], [209] were selected as potential targets for 
the development of immunodiagnostic and -therapeutic tools against TNBCs. Monoclonal 
antibodies such as trastuzumab, cetuximab, panitumumab and a range of other monoclonal 
antibodies are already in use as targeted therapies for the treatment of various cancers but an 
efficacious therapy against TNBCs has yet to be established. Current research is focusing on 
new antibody formats such as scFvs and VHHs (the formats used in this study) that have shown 
better outcomes towards diagnostics and therapy when compared to full sized antibodies 
because of their penetrative ability, reduced immunogenicity and retention in non-target 
tissues, high stability and rapid clearance from circulation [94], [95], [99]–[102].  SNAP-tag, 
as previously mentioned, is a modified version of a DNA repair enzyme that has the capacity 
to covalently bind BG-substrates in a 1:1 stoichiometry.  
In silico design of the bicistronic plasmids housing the open reading frames for our specific 
SNAP-tag based fusion proteins was performed successfully using the SNAPgene software 
(Fig. 11). The molecular cloning in this study was exemplified for αEGFR(VHH)-SNAPF but 
the same methodology was applied for each construct except for αMSLN(VHH)-SNAPF which 
did not get past the level of restriction enzyme digestion with gel electrophoresis. Previous 
studies, such as that performed by Prof Muyldermans groups at the University of Brussels, had 
used a PCR based approach to cloning the desired ORF and this could be key in getting a DNA 
concentration high enough to be seen on an agarose gel. A successful digestion (Fig. 12) was 
seen for αEGFR(VHH) out of the pUC57 vector prior to ligation into the household plasmid. 
According to general recommendations for DNA gel electrophoresis from Thermofisher 
scientific 
(https://www.thermofisher.com/content/dam/LifeTech/global/brands/Documents/1114/genera
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l-recommendations-dna-electrophoresis.pdf)  suggest that using a 1.5% agarose gel at a voltage 
of 5-10 V/cm would give us good separation of DNA in the ranges of 200-3000 bp. The lowest 
voltage was used and therefore clear separation of the DNA bands was expected. Band 
separation was seen in Figure 12, but the band intensity was quite low. Lee et al., 2012, made 
mention in a review that at least 1ug/ml of DNA would be sufficient for a successful gel 
electrophoresis experiment [210]. The concentration of 2µg/µl should have been sufficient for 
this experiment seems too low as seen by the poor band intensity. The smaller sized molecules, 
such as the VHH DNAs, normally travel faster through the agarose gels in comparison to larger 
molecules [210], [211] and it is possible that most of the DNA ran off the gel during 
electrophoresis. An unsuccessful enzyme digestion was seen for αMSLN(VHH) and perhaps 
increasing the concentration and further decreasing the voltage may provide better results. An 
additional control to the single and undigested controls may have been a DNA sample 
previously confirmed to be correct by sequencing, this may have further validated this 
experiment. The potential of having to use higher concentrations for the initial molecular 
cloning of the VHH constructs adds additional time and labour to the development process, 
also incurring more expenses as more resources are being used which may be a major downside 
for large scale experiments. 
The digested products, namely the pCB plasmid and the genes of interest, were ligated and 
transformed into DH5α E. coli competent cells. This particular strain of competent cells were 
selected for transformation because of their well-known ability to maintain and amplify 
plasmid DNA [212]. Colony growth on the agar plates (supplemented with Ampicilin) showed 
that the plasmid constructs had been successfully tranformed into the competent cells (Fig. 13). 
This is confirmed by the presence of the Ampicilin resistance (AmpR) in the plasmid (Fig. 11). 
The lack of growth in the vector only control further substantiated that the non-transformed 
bacteria could not grow in  the absence of the survival gene or in the presence of antibiotic 
selection pressure. This also showed that there were no contaminants in the plasmid samples. 
The introduction of bacteria only (with & without ampicillin) and vector with ligase controls 
may have been key to test the activity of the stock of ampicillin (with ampicillin) and the 
viability of the stock of bacteria used (without ampicillin). The digested vector with ligase 
control would test for religation of the vector but growth would not be expected on this plate 
because it would lack the open reading frame and the promoter site necessary to activate the 
the AmpR gene. This is also a good marker for potential contamination on the agar plates. 
Although these controls were not included, the digested vector only control and the successful 
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colony formations in the 1:3 and 1:5 plates were sufficient evidence to show that the ligation 
reaction. Colonies were selected from the 1:3 plate and these showed a transformation 
efficiency of 57.2 x 103 CFU/µg. The suggested maximum transformation efficiency for 1µg 
of DNA into DH5-α cells is in the range of 106-109 CFU/µg [213]. Upon visual inspection of 
the plates, there were small number of colonies which corroborated the efficiency results. 
However, the results from Inqaba biotech sequencing (Fig. 14) showed 100% identity to the 
original sequence and the restriction mapping analysis (Fig. 15) showed similar banding 
patterns to the simulated gel.  
The plasmids containing the confirmed gene of interest were transfected into Human 
embryonic kidney 293T (HEK293T) cells. As previously stated, this cell line is derived from 
HEK293 cells. The cell line origin lacks the large T antigen which is important for the 
replication of plasmids containing the SV40 promoter site. This site ensures plasmid 
transcription into proteins in this transient expression system [214], [215]. The SV40 promoter 
site is also a feature specified in the plasmid as denoted in Fig. 11 which initiates the replication 
process. During the initial 2-3 weeks of tissue culture, the cultures were enriched for with 
Zeocin™ treatment. This is a selection marker (ranked higher than the selection efficacy of 
hygromycin B, puromycin & neomycin) used to obtain the desired pool of recombinant cells 
i.e. successfully transfected cells, while suppressing the growth of non-transfected cells. The 
Zeocin/Bleomycin resistant gene is included in the architecture of the transfected plasmid 
[216]. Direct monitoring of recombinant proteins for timely harvesting at peak protein 
production has yet to be demonstrated in these types of cells and proteins but biosensors have 
been used in previous studies to follow human recombinant proteins such as the human insulin 
analogue (HI3) [217]. The addition of biosensors tailored to follow protein production in these 
cells may serve beneficial in knowing the peak times to harvest proteins, however, this would 
add an additional expense to this production process and more inexpensive avenues may need 
to be explored first. The cultures containing cells transfected with the plasmid carrying 
αEGFR(VHH)-SNAPF showed full EGFP expression ~5-6 weeks after culture and were ready 
for harvest, whereas the cultures with cells transcfected with the scFv reached a full EGFP 
expressing culture ~12 weeks after culturing (Fig. 16). The scFv transfected cells were thawed 
from lab collection and it was unusual to see these cells take a longer period of time to reach 
100% confluency and EGFP expression. Perhaps the handling protocols for the cells resulted 
in the cells becoming stressed and thus resulting in difficulty to express proteins in that state. 
It can further speculated that the small size of the VHH contanining plasmid allowed for the 
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EGFP to be translated and expressed faster than the scFv containing plasmids but the protocols 
would still need to be optimized before anything conclusive can be made. Historically, 
nanobodies in particular VHHs, have been produced in bacterial expression systems such as E. 
coli but they have also been reported to be produced in filamentous fungi and certain yeasts 
species such as as Saccharomyces cerevisiae and Pichia pastoris [103], [218]–[221]. It may 
have been an interesting experiment to compare the most efficient expression system for both 
scFv and VHH-SNAP fusion proteins. Currently,  the expression capacity of the scFv fusion 
proteins in bacteria, yeast and mammalian (used in this study) systems are being investigated 
and systems optimized. Comparing these systems may be beneficial to see which produces full 
length functional protein in the shortest time with minimal immunogenicity in vivo, while using 
the least amount of resources. The proteins were harvested from the transient mammalian 
expression system and purified by IMAC. This is a process that purifies his-tagged protein 
through the interactions with metals (in our case Ni2+) and specific amino acid side chains 
within the column resin [222], [223]. The proteins were harvested after the cells showed bright 
EGFP expressions but a more quantitative method of tracking the protein concentration in 
culture is by the use of an Elisa. By coating the plates with an anti-SNAP antibody and 
incubating with the appropriate 2o antibody, quantification of protein concentration could be 
measured in culture based on the results of the Elisa. The proteins were confirmed using SDS 
and western blotting (Fig. 19 & 20). The SDS gel showed bands at the correct sizes as decribed 
in Table 10. An additional purification step such as size exclusion chromatography (SEC) may 
have provided a cleaner protein product. This is a purification technique that separates solutes 
according to their molecular weight using the size exclusion effect of a porous gel in a column 
[224], and in essence isolating the desired protein. In Figure 19, a PVDF membrane was stained 
with ponceau red stain and this showed a banding pattern resembling that of the SDS gel 
impying a successful transfer of proteins from an SDS gel. A successful gel doc image could 
not be generated but this did not hinder the downstream processes as successful conjugation of 
the proteins to BG-Alexa488 showeded that the SNAP-tag a the C/N terminal of the protein 
was functional (Fig. 21).  After optimization of protocols, a gel doc image for the VHH protein, 
after incubation with 1o anti-His antibody was shown. This showed that the full length protein 
was present and further confirmed through conjugation with the BG-fluorophore. Although the 
yeast and bacterial expression systems are still being optimized, it is known that full length 
VHH proteins are traditionally produced in bacterial and yeast expression systems. This study 
showed a successful VHH protein product (fused to SNAP-tag) produced in a mammalian 
expression system.   
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The EGFP expression profiles were analyzed using flow cytometry. The histograms generated 
using FlowJo show that within each repeat there were a mixture of negative and postive EGFP 
expressing cells. The average EGFP expression for αCSPG4(scFv)-SNAP was recorded at 
48.4% (Fig. 17A), αMSLN(scFv)-SNAP was recorded at 51.56% (Fig. 17B), αEGFR(scFv)-
SNAP was recorded at 45.8% (Fig. 17D) and αEGFR(VHH)-SNAPF was recorded at 44.3% 
(Fig. 17C). This flow cytometry experiment could have been further refined with the addition 
of a live/dead stain such as 7-aminoactinomycin D (7AAD). The 7AAD differentiates between 
viable, apoptotic and dead cells in flow cytometry [225] and this may have been useful in 
reducing potential background flourescence from the cells in the cytometer and give us less 
skewed data. Unfortunately this was not available at the time of the experiment. Even so, 
interestingly, the VHH constructs, after being in culture for a shorter period compared to the 
scFvs could still provide competitive EGFP expression profiles. This suggests that the VHH 
proteins can be produced quicker as compared to the scFvs. There is evidence that suggests 
that the single domain antibodies are more easily produced due to their small size which allows 
for folding to happen quite rapidly, with increased hydrophobicity and no mispairing of 
domains [103], [226]–[228]. A direct correlation between percentage EGFP expression and 
protein concentration could not be made as the values varied for each targetting protein as seen 
in Table 14. A cell density monitoring study may be useful in predicting the optimal protein 
production level based on the amount of cells present in culture. Previous studies have stated 
that cell density has a direct impact on the efficiency of protein production and yield [229], 
[230]. The peak cell concentration of HEK293T cells in microcarriers have been indicated to 
be 1.5 x 106 cells/ml but in tissue culture flasks (with sizes ranging from 25-186 cm2) have 
been estimated between 2.8-20.5 x 106 cells/ml [231], [232]. Tracking the cell culture densities 
and measuring the protein concentrations at various time points may provide essential data 
toward predicting the optimal protein harvesting times from cell cultures. This quantitative data 
would allow proper comparisons regarding to be made regarding transfection efficiencies, 
percentage EGFP expression and protein concentrations. Although a correlation could not be 
made in this study, there is evidence that suggests the VHH antibody formats possess 
favourable characteristics in comparison to the scFv antibody format. The VHH (~15 kDa) is 
smaller in size than the scFv (~27 kDa) and is easier to genetically engineer or modify, it has 
better tumor penetration and shorter half lives in circulation [101], [233]–[236], as 
demonstrated by Prof. Muyldermans group and various others. There are signs that the VHH 
antibody format may potentially outperform the scFv but its effectiveness when fused to 
SNAP-tag is uknown at the moment.   
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The proteins were successfully conjugated to BG-modified Alexa 488 (fluorophore) as shown 
in Figure 21, and efficiency data generated from this as well (Table 14). In Figure 21, we see 
that the band flourescence of the αEGFR(VHH)-SNAPf-Alexa488 conjugation product is 
brighter than its scFv counterparts, even though it showed the second highest conjugation 
efficiency at 54.65% (Table 14). This speaks to the efficiency of the SNAP-F variant which 
allows for labelling with BG-substrates to occur faster and more efficiently than the original 
SNAP-tag format [237]. The conjugated proteins were used in binding studies with receptor 
positive tumor cell lines. The cell lines used for test for binding were Hs578t (CSPG4+), MB-
MDA-468 (CSPG4-, EGFR+) and A2058 (EGFR-). Cell lines strongly expressing the MSLN 
receptor could not be acquired and therefore no binding studies were recorded for 
αMSLN(scFv)-SNAP. In Figure 22, a clear membrane signal was seen for cells labelled with 
αCSPG4(scFv)-SNAP (Fig. 22A) and αEGFR(VHH)-SNAPF (Fig. 22C). The cells labelled 
with αEGFR(scFv)-SNAP (Fig. 22B) were slightly stressed due to them being put on ice prior 
to them being viewed on the confocal microscope. It was previously thought that placing cells 
on ice would slow down internalization of labelled protein but later seen that this was 
unnecessary. Nevertheless, A partial membrane signal could still be seen on the membranes of 
these cells. The αEGFR(VHH)-SNAPF proteins showed better accumulation of proteins on the 
surface as compared to the scFv proteins. There was partial internalization aswell in these cells. 
These results further confirm the fast binding and tissue penetrative ability of VHHs [100], 
[103], [238]. The results obtained in this study coincide with the general literature on these 
three targets. There has been extensive research on EGFR and CSPG4 on a variety of cancer 
types, in particular melanoma, prostatic and breast cancers [192], [239]–[243], but there is 
limited knowledge and understanding about MSLN and more work can be done in closing this 
gap in knowledge. Nonetheless, protein binding to target epitopes on TNBC cell lines was 
shown using two different antibody formats recombinantly fused to SNAP-tag. This is 
especially important for EGFR overexpressing tumours as there may potentially be a fast 
binding and highly specific method of diagnosis and therapy in the VHH-SNAP fusion 
proteins.  
4.2  Conclusion & Future perspectives 
The primary aim of the study was to design, produce and show functionality, in terms of 
binding capacity, of surface antigen targeting SNAP-tag fusion proteins against the three study 
specific surface receptors overexpressed in TNBCs with the greater goal of improving the 
current scope of cancer diagnosis and therapy. This study showed functionality of two scFv 
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SNAP fusion proteins and one VHH SNAP fusion protein. Previously there had not been any 
reports on the combition of a VHH antibody format with SNAP-tag technology and therefore 
this study has provided novelty towards scientific research that can be built upon. Theoretically, 
this technology can allow the design, production and potentially show functionality of any 
protein targeting surface receptors expressed on a variety of diseases, provided the sequences 
can be obtained. SNAP-tag has shown great potential as an immunodiagnostic agent as it allows 
for the tracking of tagged proteins in vivo and visualisation of cell to cell interactions. This 
technology can contribute towards possible therapies by attaching a BG-modified drug or toxic 
to a SNAP-tag fusion protein that target specific epitopes on diseased cells [244]–[247]. This 
study also partially demonstrated the effieciency of SNAP-F variant against SNAP-tag. In a 
study by Sun et al, 2011, they were able to show, by way of kinetics measurements using 
fluorogenic probes, that SNAP-F binds BG-substrates 10-fold faster than SNAP-tag. 
Furthermore, they showed binding data by using HEK293 cells that were stably expressing 
EGFR and, by using an EGFR targeting antibody fused to SNAPF, they were able to show 
membrane fluorescence in the presence and absence of media [123]. In this study, similar 
binding and fluorescence intensities on tumour cell lines were shown. This result further 
contributes to the greater goal of improved immunodiagnostic and therapeutic agents but a 
more in depth investigation would need to be performed. The next step would be to confirm 
binding on patient biopsies and in animal models. The VHH has been shown to be well 
expressed in a variety of expression systems due to its single domain nature and increased 
hydrophobicity. It is physiologically stable, highly soluble, easily modified genetically and 
shows fast tissue penetration and clearance [101]–[103], [227], [228], [238]. The combination 
with SNAP-tag allows for the covalent binding of the fusion protein with any BG-modified 
probe such as a fluorophore that can be tracked on the surface or in the internal compartments 
of cells; or an immunotoxin that can provide effective killing of diseased tissues without 
harming healthy tissues. Protein engineering has changed the scope of immunodiagnostics and 
therapy by allowing the creative design of novel targeting proteins and their conjugation to 
reporter probes or toxic payloads. The combination of VHH and SNAP-tag is such an example 
of the progress being made in this field. A fusion protein that is capable of binding quickly and 
specifically to its target epitope but also has the ability to covalently bind any BG-substrate in 
a 1:1 ratio is as a result of this study and advancements made in this field. The combination of 
targetting antibodies and SNAP-tag technology has opened the door for further medical 
advancements and invention in immunotherapy. It has, for example, initiated a collaboration 
of the Medical Biotechnology & Immunotherapy (MB&I) Research Unit with  Prof 
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Klumperman’s group at Department of Chemistry and Polymer Science at Stellenbosch 
University where a polymer with a BG-moeity is being synthesized. Historically polymers have 
been used as vehicles for drug delivery but the problem is that this mode of therapy is unspecific 
[248] and the addition an antibody may remedy this. Moreover, the combination of these 
technologies may provide novel and innovative ways towards disease diagnosis and therapy. 
This study had hoped to add another brick onto the foundation of immunodiagnostics and 
immunotherapy. This study showcased the design, production and functionality of SNAP-tag 
fusion proteins as target specific molecules detection molecules against TNBC. These 
molecules were designed to ensure key additions in the discovery of newer, safer and more 
efficient methods of disease diagnosis and therapy that can potentially replace the current state 
of the art. The study made use of multidisciplined approach, in terms of the methodology 
employed, in order to show the functionality of the proteins and the novelty of SNAP-tag fused 
nanobodies. Overall, key successes relating to the primary aims were noted during the study 
but improvements can be made to strengthen the reliability of the presented data and these were 
previously suggested. The current model makes use of an in vitro approach to test and qualify 
the functionality of SNAP-tag fusion proteins but it may be important to show the same target 
specificty and detectability in vivo. This future recommendation may greatly contribute to the 
immunodiagnostic arm of the primary aims. Future recommendations towards the 
immunotherapeutic arm include testing the scFv and VHH SNAP-tag proteins using BG-
modified cytotoxic agents such as monomethyl Auristatin-E/F (MMAE/F). MMAE or MMAF 
are small molecule toxins that exerts their effects after target specific delivery to a cell [249]. 
It is speculated that this would show targetted killing of diseased cells rich with the target 
receptor while preserving healthy cells. Successful cell death experiments have been performed 
by colleagues, Dr Nsole and Ms Jordaan, using the scFv antibody formats of αCSPG4-MMAF 
and αEGFR-MMAF give confidence that these results can be reproduced for the VHH format 
aswell. This study sought to add to novelty to this field and further build on work previously 
performed. This study has provided new knowledge to build upon in the form of SNAP-tag 
fused nanobodies and these may provide novel combinations that contribute towards 
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